<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Rheumatol Immunol Res</journal-id><journal-id journal-id-type="iso-abbrev">Rheumatol Immunol Res</journal-id><journal-id journal-id-type="pmc-domain-id">4299</journal-id><journal-id journal-id-type="pmc-domain">rir</journal-id><journal-id journal-id-type="publisher-id">rir</journal-id><journal-title-group><journal-title>Rheumatology and Immunology Research</journal-title></journal-title-group><issn pub-type="epub">2719-4523</issn><publisher><publisher-name>De Gruyter</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10538607</article-id><article-id pub-id-type="pmcid-ver">PMC10538607.1</article-id><article-id pub-id-type="pmcaid">10538607</article-id><article-id pub-id-type="pmcaiid">10538607</article-id><article-id pub-id-type="pmid">37781681</article-id><article-id pub-id-type="doi">10.2478/rir-2023-0020</article-id><article-id pub-id-type="publisher-id">rir-2023-0020</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Peptide-based immunotherapy in lupus: Where are we now?</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3203-4454</contrib-id><name name-style="western"><surname>P. Singh</surname><given-names initials="R">Ram</given-names></name><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:ram.singh@va.gov">ram.singh@va.gov</email><xref rid="j_rir-2023-0020_aff_001" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>S. Bischoff</surname><given-names initials="D">David</given-names></name><xref rid="j_rir-2023-0020_aff_001" ref-type="aff"/><xref rid="j_rir-2023-0020_aff_002" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>S Singh</surname><given-names initials="S">Satendra</given-names></name><xref rid="j_rir-2023-0020_aff_003" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>H. Hahn</surname><given-names initials="B">Bevra</given-names></name><xref rid="j_rir-2023-0020_aff_002" ref-type="aff"/></contrib><aff id="j_rir-2023-0020_aff_001"><institution>Research Service, Veteran Administration Greater Los Angeles Healthcare System</institution>, <city>Los Angeles</city>, <postal-code>90073 CA</postal-code>, <country country="US">USA</country></aff><aff id="j_rir-2023-0020_aff_002"><institution>Department of Medicine, University of California, Los Angeles</institution>, <city>Los Angeles</city>, <postal-code>90095 CA</postal-code>, <country country="US">USA</country></aff><aff id="j_rir-2023-0020_aff_003"><institution>Cedars-Sinai Medical Center</institution>, <city>Beverly Hills</city>, <postal-code>90048 CA</postal-code>, <country country="US">USA</country></aff></contrib-group><author-notes><corresp>Research Service, Veteran Administration Greater Los Angeles, Healthcare System, Los Angeles, 90073 CA, USA.</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>27</day><month>9</month><year>2023</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>9</month><year>2023</year></pub-date><volume>4</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">446266</issue-id><fpage>139</fpage><lpage>149</lpage><history><date date-type="received"><day>1</day><month>6</month><year>2023</year></date><date date-type="accepted"><day>1</day><month>8</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>27</day><month>09</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>29</day><month>09</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-01-25 16:25:10.463"><day>25</day><month>01</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 Ram P. Singh, David S. Bischoff, Satendra S Singh, Bevra H. Hahn, published by De Gruyter on behalf of NCRC-DID.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Ram P. Singh, David S. Bischoff, Satendra S Singh, Bevra H. Hahn, published by De Gruyter on behalf of NCRC-DID.</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under the Creative Commons Attribution 4.0 International License.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="rir-4-3-rir-2023-0020.pdf"/><abstract><title>Abstract</title><p>In autoimmune rheumatic diseases, immune hyperactivity and chronic inflammation associate with immune dysregulation and the breakdown of immune self-tolerance. A continued, unresolved imbalance between effector and regulatory immune responses further exacerbates inflammation that ultimately causes tissue and organ damage. Many treatment modalities have been developed to restore the immune tolerance and immmunoregulatory balance in autoimmune rheumatic diseases, including the use of peptide-based therapeutics or the use of nanoparticles-based nanotechnology. This review summarizes the state-of-the-art therapeutic use of peptide-based therapies in autoimmune rheumatic diseases, with a specific focus on lupus.</p></abstract><kwd-group><title>Keywords</title><kwd>peptide</kwd><kwd>immune tolerance</kwd><kwd>lupus</kwd><kwd>regulatory T cells</kwd><kwd>immunotherapy</kwd><kwd>cytokine</kwd><kwd>chemokine</kwd></kwd-group><funding-group><funding-statement>This work was supported by the NIH grants AR54034, AI 083894, AI65645 to RPS; UCLA Senate Core Grant to BHH and RPS; UCLA Oppenheimer Clinical Seed Grant and American Autoimmune Related Disease Association grant to RPS.</funding-statement></funding-group><counts><page-count count="11"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="j_rir-2023-0020_s_001"><title>Introduction</title><p>Autoimmune rheumatic diseases carry a significant burden of morbidity and mortality and have a substantial economic impact on both individuals and the society as a whole.<sup>[<xref rid="j_rir-2023-0020_ref_001" ref-type="bibr">1</xref>, <xref rid="j_rir-2023-0020_ref_002" ref-type="bibr">2</xref>, <xref rid="j_rir-2023-0020_ref_003" ref-type="bibr">3</xref>, <xref rid="j_rir-2023-0020_ref_004" ref-type="bibr">4</xref>]</sup> Despite extensive research, the precise cellular and molecular mechanisms that drive the pathogenesis of those conditions are only partly understood, with a resulting variety of therapeutic approaches that depend on the symptoms, signs, and stage of the disease.</p><p>In systemic lupus erythematosus (SLE), corticosteroids are widely used to manage inflammation including in lupus nephritis, yet they carry significant side effects.<sup>[<xref rid="j_rir-2023-0020_ref_005" ref-type="bibr">5</xref>]</sup> Other immunosuppressive agents, including disease-modifying anti-rheumatic drugs (DMARDs) and biological therapies have shown some efficacy in inducing long-term remission but carry the risk of adverse events including the development of malignancy.<sup>[<xref rid="j_rir-2023-0020_ref_006" ref-type="bibr">6</xref>,<xref rid="j_rir-2023-0020_ref_007" ref-type="bibr">7</xref>]</sup> In addition, treatments with biologics can be costly and increase the risk of systemic immune suppression.<sup>[<xref rid="j_rir-2023-0020_ref_008" ref-type="bibr">8</xref>]</sup></p><p>A safe alternative to the use of drugs carrying important side effects has been the use of peptide-based tolerogenic therapeutics for the induction of immune tolerance to self-antigens though the inhibition of autoreactive T, B, and dendritic cells together with the promotion of the activity of immunoregulatory cell populations.<sup>[<xref rid="j_rir-2023-0020_ref_009" ref-type="bibr">9</xref>, <xref rid="j_rir-2023-0020_ref_010" ref-type="bibr">10</xref>, <xref rid="j_rir-2023-0020_ref_011" ref-type="bibr">11</xref>]</sup> We discuss below the promise of peptide-based immunotherapies and related clinical trials.</p></sec><sec id="j_rir-2023-0020_s_002"><title>Peptide-Based Therapeutics</title><p>Peptide-based therapeutics can be broadly categorized into two categories that are based on their chief mechanism of action: immunogenic or tolerogenic. Immunogenic peptide therapy induces an immune response against a specific antigen, whereas the tolerogenic peptide therapy induces immune tolerance to self-antigens.</p><p>Immunogenic peptide therapy aims to activate the immune system to a specific antigen by presenting it to the immune cells in a way that mimics a natural infection.<sup>[<xref rid="j_rir-2023-0020_ref_012" ref-type="bibr">12</xref>, <xref rid="j_rir-2023-0020_ref_013" ref-type="bibr">13</xref>, <xref rid="j_rir-2023-0020_ref_014" ref-type="bibr">14</xref>]</sup> Although this approach has mainly been used in cancer immunotherapy to activate cytotoxic T lymphocytes (CTLs) against tumor antigens, several immunogenic peptide therapeutics have been developed as well for autoimmune diseases including SLE,<sup>[<xref rid="j_rir-2023-0020_ref_015" ref-type="bibr">15</xref>,<xref rid="j_rir-2023-0020_ref_016" ref-type="bibr">16</xref>]</sup> rheumatoid arthritis,<sup>[<xref rid="j_rir-2023-0020_ref_017" ref-type="bibr">17</xref>,<xref rid="j_rir-2023-0020_ref_018" ref-type="bibr">18</xref>]</sup> type 1 diabetes,<sup>[<xref rid="j_rir-2023-0020_ref_019" ref-type="bibr">19</xref>,<xref rid="j_rir-2023-0020_ref_020" ref-type="bibr">20</xref>]</sup> and multiple sclerosis,<sup>[<xref rid="j_rir-2023-0020_ref_021" ref-type="bibr">21</xref>]</sup> with varying success.</p><p>Tolerogenic peptide therapy aims instead to induce immune tolerance to self-antigens by selectively targeting and suppressing self-reactive T cells, while promoting the expansion of regulatory T cells (T<sub>regs</sub>) and tolerogenic dendritic cells (DCs).<sup>[<xref rid="j_rir-2023-0020_ref_022" ref-type="bibr">22</xref>, <xref rid="j_rir-2023-0020_ref_023" ref-type="bibr">23</xref>, <xref rid="j_rir-2023-0020_ref_024" ref-type="bibr">24</xref>, <xref rid="j_rir-2023-0020_ref_025" ref-type="bibr">25</xref>, <xref rid="j_rir-2023-0020_ref_026" ref-type="bibr">26</xref>, <xref rid="j_rir-2023-0020_ref_027" ref-type="bibr">27</xref>, <xref rid="j_rir-2023-0020_ref_028" ref-type="bibr">28</xref>]</sup> This approach has been tested in several autoimmune diseases, including SLE, rheumatoid arthritis and multiple sclerosis. Tolerogenic peptide therapy can be further subcategorized according to the type of peptide(s) used, specifically:</p><p>(1) Epitope-specific peptides: These peptides are derived from specific epitopes of self-antigens and are used to selectively target autoreactive T cells.<sup>[<xref rid="j_rir-2023-0020_ref_029" ref-type="bibr">29</xref>, <xref rid="j_rir-2023-0020_ref_030" ref-type="bibr">30</xref>, <xref rid="j_rir-2023-0020_ref_031" ref-type="bibr">31</xref>]</sup> They can be delivered alone or in combination with immunomodulatory agents.</p><p>(2) Whole protein peptides: These peptides are derived from full-length self-proteins and can induce a broader immune response against multiple epitopes of the protein. They can be used to induce immune tolerance or to modulate the immune response in autoimmune diseases.<sup>[<xref rid="j_rir-2023-0020_ref_013" ref-type="bibr">13</xref>,<xref rid="j_rir-2023-0020_ref_032" ref-type="bibr">32</xref>,<xref rid="j_rir-2023-0020_ref_033" ref-type="bibr">33</xref>]</sup></p><p>(3) Mimotopes: They are typically a series of linear overlapping peptides designed to pinpoint either T cell or antibody epitopes and can be used to induce immune tolerance and/or to activate regulatory immune cells.<sup>[<xref rid="j_rir-2023-0020_ref_034" ref-type="bibr">34</xref>, <xref rid="j_rir-2023-0020_ref_035" ref-type="bibr">35</xref>, <xref rid="j_rir-2023-0020_ref_036" ref-type="bibr">36</xref>]</sup></p></sec><sec id="j_rir-2023-0020_s_003"><title>Strategies for Peptide-Based Therapy</title><p>A central characteristic of autoimmune diseases is the breakdown of self-tolerance with the activation of autoreactive immune cells that secrete pro-inflammatory cytokines and chemokines that amplify inflammation.</p><p>Two different strategies have been proposed to target these key aspects of the pathogenesis of autoimmunity<sup>[<xref rid="j_rir-2023-0020_ref_037" ref-type="bibr">37</xref>]</sup> (<xref rid="j_rir-2023-0020_tab_001" ref-type="table">Table 1</xref>).</p><table-wrap position="float" id="j_rir-2023-0020_tab_001" orientation="portrait"><label>Table 1</label><caption><p>Comparison of two peptide-based therapeutic strategies in autoimmune diseases including SLE</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Comparative items</th><th align="left" rowspan="1" colspan="1">Peptide-based active therapy against proinflammatory cytokines</th><th align="left" rowspan="1" colspan="1">Peptide-based tolerogenic therapy</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Source of peptides</td><td align="left" rowspan="1" colspan="1">Pro-inflammatory cytokines</td><td align="left" rowspan="1" colspan="1">Self-antigens, TCRs</td></tr><tr><td align="left" rowspan="1" colspan="1">Therapeutic targets</td><td align="left" rowspan="1" colspan="1">Pro-inflammatory cytokines</td><td align="left" rowspan="1" colspan="1">Autoimmune attacks against host cells or tissues</td></tr><tr><td align="left" rowspan="1" colspan="1">Main effects</td><td align="left" rowspan="1" colspan="1">Induced production of neutralizing antibodies</td><td align="left" rowspan="1" colspan="1">Immune tolerance to self-antigens through the inhibition of autoreactive lymphocytes and induction of T<sub>regs</sub></td></tr><tr><td align="left" rowspan="1" colspan="1">Adjuvant</td><td align="left" rowspan="1" colspan="1">Adjuvant required</td><td align="left" rowspan="1" colspan="1">Not necessary</td></tr><tr><td align="left" rowspan="1" colspan="1">Relevant immune cells</td><td align="left" rowspan="1" colspan="1">Mainly B cells</td><td align="left" rowspan="1" colspan="1">Autoreactive T cells, T<sub>regs</sub> (CD4<sup>+</sup> and CD8<sup>+</sup>), tol DCs and other APCs</td></tr><tr><td align="left" rowspan="1" colspan="1">Evidence from clinical trials</td><td align="left" rowspan="1" colspan="1">Limited</td><td align="left" rowspan="1" colspan="1">Limited</td></tr><tr><td align="left" rowspan="1" colspan="1">Diseases</td><td align="left" rowspan="1" colspan="1">SLE, RA, SjS</td><td align="left" rowspan="1" colspan="1">SLE, RA, SjS</td></tr></tbody></table><table-wrap-foot><fn><p>T<sub>regs</sub>: regulatory T cells; tol DCs: tolerogenic dendritic cells; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; SjS: Sj&#246;gren&#8217;s syndrome; TCRs: T cell receptors; APC: antigen presenting cells.</p></fn></table-wrap-foot></table-wrap><p>The first strategy aims to antagonize proinflammatory cytokines and chemokines that induce and sustain inflammation and favor the development of tissue damage.<sup>[<xref rid="j_rir-2023-0020_ref_038" ref-type="bibr">38</xref>, <xref rid="j_rir-2023-0020_ref_039" ref-type="bibr">39</xref>, <xref rid="j_rir-2023-0020_ref_040" ref-type="bibr">40</xref>, <xref rid="j_rir-2023-0020_ref_041" ref-type="bibr">41</xref>]</sup> This approach produces neutralizing antibodies (nAbs) against these proinflammatory biomolecules to inhibit their activities. In this strategy, the target immune cells are mostly B cells.</p><p>The second strategy involves the development of peptide-based tolerogenic molecules that aim to restore immune homeostasis and rebalance immune dysregulation.<sup>[<xref rid="j_rir-2023-0020_ref_009" ref-type="bibr">9</xref>,<xref rid="j_rir-2023-0020_ref_010" ref-type="bibr">10</xref>,<xref rid="j_rir-2023-0020_ref_022" ref-type="bibr">22</xref>,<xref rid="j_rir-2023-0020_ref_024" ref-type="bibr">24</xref>,<xref rid="j_rir-2023-0020_ref_025" ref-type="bibr">25</xref>,<xref rid="j_rir-2023-0020_ref_027" ref-type="bibr">27</xref>,<xref rid="j_rir-2023-0020_ref_028" ref-type="bibr">28</xref>,<xref rid="j_rir-2023-0020_ref_042" ref-type="bibr">42</xref>, <xref rid="j_rir-2023-0020_ref_043" ref-type="bibr">43</xref>, <xref rid="j_rir-2023-0020_ref_044" ref-type="bibr">44</xref>, <xref rid="j_rir-2023-0020_ref_045" ref-type="bibr">45</xref>, <xref rid="j_rir-2023-0020_ref_046" ref-type="bibr">46</xref>]</sup> The target immune cells in this strategy are autoreactive T cells, regulatory T cells (T<sub>regs</sub>), and tolerogenic dendritic cells (tol DCs), as schematized in <xref rid="j_rir-2023-0020_fig_001" ref-type="fig">Figure 1</xref> for SLE.</p><fig position="float" id="j_rir-2023-0020_fig_001" fig-type="figure" orientation="portrait"><label>Figure 1</label><caption><p>The role of peptide induced immune tolerance in SLE. A: In the autoimmune state, the CD4<sup>+</sup> and CD8<sup>+</sup> T cells are activated, and Dendritic cells (DCs) become aggressive and create autoimmune activation and further inflammation in SLE. B: In the tolerance state, peptide-induced tolerization promotes the expansion of antigen-specific regulatory cells and further tolerizes dendritic cells (DCs). These tolerized dendritic cells induce deletion and anergy of cognate T cells and further modulate regulatory T cells in SLE. These peptide induced regulatory T cells (T<sub>regs</sub>) which suppress the autoreactive/autoimmune responses in SLE.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="j_rir-2023-0020_fig_001.jpg"/></fig><p>Although peptide-based therapeutic approaches have shown promising results in inducing immune tolerance in autoimmune diseases, an optimization of the design and delivery of the peptides is still crucial to improve clinical efficacy.<sup>[<xref rid="j_rir-2023-0020_ref_047" ref-type="bibr">47</xref>]</sup></p></sec><sec id="j_rir-2023-0020_s_004"><title>Peptide-based Therapy against Pro-inflammatory Cytokines/Chemokines</title><p>Since pro-inflammatory cytokines and chemokines play a critical role in the pathogenesis of many autoimmune diseases, peptide-based vaccines have been designed to antagonize the pro-pathogenic cytokines and chemokines to reduce inflammation and tissue damage.</p><p>Modified peptides can target pro-inflammatory cytokines or chemokine receptors selectively. For example, a modified DNA peptide therapy targeting pro-inflammatory interleukin (IL)-17 significantly reduced organ damage and increased the survival of treated lupus-prone mice,<sup>[<xref rid="j_rir-2023-0020_ref_048" ref-type="bibr">48</xref>]</sup> while targeting the CXC chemokine ligand 10 (CXCL10) attenuated experimental autoimmune encephalomyelitis.<sup>[<xref rid="j_rir-2023-0020_ref_049" ref-type="bibr">49</xref>]</sup> Of interest, a peptide therapy targeting pro-inflammatory tumor necrosis factor alpha (TNF-&#945;) induced the generation of T<sub>regs</sub> and reduced inflammation in a mouse model of collagen induced arthritis.<sup>[<xref rid="j_rir-2023-0020_ref_050" ref-type="bibr">50</xref>,<xref rid="j_rir-2023-0020_ref_051" ref-type="bibr">51</xref>]</sup></p><p>Potential biologics have been generated to target pro-inflammatory cytokines, such as IL-1, interferon (IFN)-&#945;, IFN-&#947;, IL-6, TNF-&#945;, IL-17, and IL-21, and several clinical trials that aim at inhibiting the activities of these mediators have been initiated.<sup>[<xref rid="j_rir-2023-0020_ref_052" ref-type="bibr">52</xref>]</sup> Despite the promising results in preclinical studies, there are still challenges that need to be addressed before translation into the clinic, including the identification of the optimal peptide targets and delivery methods, as well as the potential off-target effects and long-term safety.</p></sec><sec id="j_rir-2023-0020_s_005"><title>Peptide-Based Tolerogenic Therapeutics in Lupus</title><p>Recent studies both <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> have identified several peptides that are useful in lupus treatment. <xref rid="j_rir-2023-0020_tab_002" ref-type="table">Table 2</xref> indicates effects of the current peptide therapeutics in lupus.</p><table-wrap position="float" id="j_rir-2023-0020_tab_002" orientation="portrait"><label>Table 2</label><caption><p>Salient features and effects of the current peptide therapeutics in SLE</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Peptide</th><th align="left" rowspan="1" colspan="1">Origin</th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">In Vivo</italic> Effects</th><th align="left" rowspan="1" colspan="1">Molecular Mechanisms</th><th align="left" rowspan="1" colspan="1">Administration Route</th><th align="left" rowspan="1" colspan="1">Clinical trial</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">pCons</td><td align="left" rowspan="1" colspan="1">Synthetic murine anti-dsDNA Ab</td><td align="left" rowspan="1" colspan="1">Reduced anti-DNA Ab, proteinuria; delayed nephritis and prolonged survival</td><td align="left" rowspan="1" colspan="1">Induces T<sub>regs</sub> (both CD4<sup>+</sup> and CD8<sup>+</sup>), increases TGF-b, IL-10, FOXP3</td><td align="left" rowspan="1" colspan="1">Intravenous route</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" rowspan="1" colspan="1">hCDR1 (Edratide)</td><td align="left" rowspan="1" colspan="1">CDR1 of the human anti-DNA mAb</td><td align="left" rowspan="1" colspan="1">Decreased anti-dsDNA, anti-nuclear, anti-cardiolipin Abs, and nephritis; prolonged survival</td><td align="left" rowspan="1" colspan="1">Decreased IFN- &#947;, IFN- &#945;, IL-1B, TNF-&#945;, BAFF, caspases 3 and 8, T and B cell activation, Increased CD4<sup>+</sup> and CD8<sup>+</sup> T<sub>regs</sub>, and B cell apoptosis</td><td align="left" rowspan="1" colspan="1">Subcutaneous</td><td align="left" rowspan="1" colspan="1">Double blind, Phase 2 placebo-controlled clinical trial</td></tr><tr><td align="left" rowspan="1" colspan="1">DWEYS</td><td align="left" rowspan="1" colspan="1">Anti-DNA Ab (D/E W D/E Y S/G), consensus sequence with NMDAR</td><td align="left" rowspan="1" colspan="1">Decreased anti-dsDNA Abs; amelioration of renal and CNS manifestations</td><td align="left" rowspan="1" colspan="1">Decreased binding and glomerular deposition of anti dsDNA Abs; inhibition of autoreactive B cells</td><td align="left" rowspan="1" colspan="1">Intravenous route</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" rowspan="1" colspan="1">FISLE-412</td><td align="left" rowspan="1" colspan="1">Molecular topology of DWEYS</td><td align="left" rowspan="1" colspan="1">Decreased anti-dsDNA Abs, amelioration of renal and CNS manifestations</td><td align="left" rowspan="1" colspan="1">Decreased binding and glomerular deposition of anti dsDNA Abs, Abs to cardiolipin, and neuronal apoptosis</td><td align="left" rowspan="1" colspan="1">Oral</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" rowspan="1" colspan="1">ALW</td><td align="left" rowspan="1" colspan="1">Four types of murine anti-dsDNA IgG mAbs</td><td align="left" rowspan="1" colspan="1">Decreased anti-dsDNA Abs; amelioration of renal manifestations</td><td align="left" rowspan="1" colspan="1">Decreased laminin, CTGF, TGF-b, PDGF-B, anti-DNA Ab binding/glomerular deposition; renal inflammation</td><td align="left" rowspan="1" colspan="1">Intravenous route</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" rowspan="1" colspan="1">Nucleo-somal histone peptide</td><td align="left" rowspan="1" colspan="1">Endogenous peptide epitopes in histone from nucleosome</td><td align="left" rowspan="1" colspan="1">Decreased pathogenic autoantibody production, renal inflammation, B cell activation</td><td align="left" rowspan="1" colspan="1">Induced both CD4<sup>+</sup> and CD8<sup>+</sup> T<sub>regs</sub></td><td align="left" rowspan="1" colspan="1">Subcutaneous intranasal, intraperitoneal</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" rowspan="1" colspan="1">LJP-394 (Abetimus)</td><td align="left" rowspan="1" colspan="1">Synthetic tolerogen (4 oligo-nucleotides attached to niPEG)</td><td align="left" rowspan="1" colspan="1">Decreased anti-dsDNA Abs</td><td align="left" rowspan="1" colspan="1">Binds to cross-linking surface Abs</td><td align="left" rowspan="1" colspan="1">Intravenous</td><td align="left" rowspan="1" colspan="1">Phase I, II and III</td></tr></tbody></table><table-wrap-foot><fn><p>SLE, systemic lupus erythematosus; TGF-&#946;, transforming growth factor &#946;; FOXP3, Forkhead box protein P3; SOCS-1 suppression of cytokine signaling-1, PDGF-B, platelet-derived growth factor-B; CTGF, connective tissue growth factor; CNS, central nervous system; Abs, antibodies; niPEG, non-immunogenic polyethylene glycol; N/A, not available. Modified from ref [86], Springer.</p></fn></table-wrap-foot></table-wrap><sec id="j_rir-2023-0020_s_005_s_001"><title>pCons Peptide</title><p>pCons (pConsensus-FIEWNKLRFRQGLEW) is a 15-mer peptide, derived from the V<sup>H</sup> regions of anti-DNA antibodies from (NZB x NZW) F1 (BWF1) mice.<sup>[<xref rid="j_rir-2023-0020_ref_009" ref-type="bibr">9</xref>,<xref rid="j_rir-2023-0020_ref_010" ref-type="bibr">10</xref>,<xref rid="j_rir-2023-0020_ref_022" ref-type="bibr">22</xref>,<xref rid="j_rir-2023-0020_ref_027" ref-type="bibr">27</xref>,<xref rid="j_rir-2023-0020_ref_028" ref-type="bibr">28</xref>,<xref rid="j_rir-2023-0020_ref_043" ref-type="bibr">43</xref>,<xref rid="j_rir-2023-0020_ref_053" ref-type="bibr">53</xref>]</sup> pCons peptide induce immune tolerance therapy in BWF1 lupus-mice by promoting the generation of autoantigen-specific regulatory T cells that suppressed effector T cells<sup>[<xref rid="j_rir-2023-0020_ref_011" ref-type="bibr">11</xref>,<xref rid="j_rir-2023-0020_ref_054" ref-type="bibr">54</xref>]</sup> and autoantibody-producing B cells.<sup>[<xref rid="j_rir-2023-0020_ref_055" ref-type="bibr">55</xref>]</sup></p><p>pCons peptide therapy induces immune tolerance by promoting expansion of CD8<sup>+</sup> and CD4<sup>+</sup> T<sub>regs.</sub><sup>[<xref rid="j_rir-2023-0020_ref_009" ref-type="bibr">9</xref>,<xref rid="j_rir-2023-0020_ref_010" ref-type="bibr">10</xref>,<xref rid="j_rir-2023-0020_ref_022" ref-type="bibr">22</xref>,<xref rid="j_rir-2023-0020_ref_025" ref-type="bibr">25</xref>,<xref rid="j_rir-2023-0020_ref_027" ref-type="bibr">27</xref>,<xref rid="j_rir-2023-0020_ref_028" ref-type="bibr">28</xref>,<xref rid="j_rir-2023-0020_ref_053" ref-type="bibr">53</xref>,<xref rid="j_rir-2023-0020_ref_056" ref-type="bibr">56</xref>]</sup> pCons-induced T<sub>regs</sub> suppress the production of anti-dsDNA autoantibodies, reduce proteinuria, and delay nephritis in murine lupus.<sup>[<xref rid="j_rir-2023-0020_ref_022" ref-type="bibr">22</xref>,<xref rid="j_rir-2023-0020_ref_053" ref-type="bibr">53</xref>]</sup> Notably, oral administration of different forms of pCons peptide, including D and L forms, delayed anti-ds-DNA Ab production and lupus nephritis, and increased the survival of lupus mice.<sup>[<xref rid="j_rir-2023-0020_ref_057" ref-type="bibr">57</xref>]</sup></p><p>Importantly, pCons peptide induced T<sub>regs</sub> in lupus patients.<sup>[<xref rid="j_rir-2023-0020_ref_058" ref-type="bibr">58</xref>]</sup> When the lupus patients&#8217; peripheral blood mononuclear cells (PBMCs) were cultured with pCons peptide, the expansion of fully functional T<sub>regs</sub> occurred in those patients that were seropositive for anti-DNA autoantibodies. This is in line with the antigen-specificity of the response promoted by peptide immunotherapy, and resulted in the suppression by the pCons-induced T<sub>regs</sub> of the proliferation of CD4<sup>+</sup>CD25<sup>-</sup> T effectors cells and reduced production of proinflammatory cytokines.<sup>[<xref rid="j_rir-2023-0020_ref_058" ref-type="bibr">58</xref>]</sup> Clinical trials are awaited to address whether the promising effects of pCons can be translated into clinical settings.</p></sec><sec id="j_rir-2023-0020_s_005_s_002"><title>human complementarity-determing region 1 (hCDR1) (Edratide)</title><p>hCDR1 (edratide) is a 19-mer peptide based on the heavy chain complementarity-determining region one (CDR1) sequences of a human anti-DNA monoclonal antibody. Edratide reduced autoreactive T cells responses by inducing T <sub>regs</sub> and by downregulating the production of IFN-&#945; in both murine and human SLE.<sup>[<xref rid="j_rir-2023-0020_ref_025" ref-type="bibr">25</xref>,<xref rid="j_rir-2023-0020_ref_059" ref-type="bibr">59</xref>, <xref rid="j_rir-2023-0020_ref_060" ref-type="bibr">60</xref>, <xref rid="j_rir-2023-0020_ref_061" ref-type="bibr">61</xref>]</sup> Tolerization with hCDR1 induced both CD4<sup>+</sup>CD25<sup>+</sup> and CD8<sup>+</sup>CD28<sup>&#8722;</sup> T<sub>regs</sub> in mice, which suppressed lymphocyte proliferation and autoantibody production.<sup>[<xref rid="j_rir-2023-0020_ref_062" ref-type="bibr">62</xref>, <xref rid="j_rir-2023-0020_ref_063" ref-type="bibr">63</xref>, <xref rid="j_rir-2023-0020_ref_064" ref-type="bibr">64</xref>]</sup> Earlier studies had shown that hCDR1 induced anergy in antigen presenting cells (APCs) and the generation of Tr1 T<sub>regs</sub>, which expressed tolerance-associated genes.<sup>[<xref rid="j_rir-2023-0020_ref_024" ref-type="bibr">24</xref>,<xref rid="j_rir-2023-0020_ref_059" ref-type="bibr">59</xref>,<xref rid="j_rir-2023-0020_ref_060" ref-type="bibr">60</xref>]</sup> hCDR1 also downregulated IL-1&#946;, IFN-&#947;, and TNF-&#945; in addition to IFN-&#945;, and upregulated the immunosuppressive cytokine transforming growth factor-&#946; (TGF-&#946;). It also reduced expression of Lymphocyte function-associated antigen 1 (LFA-1) and CD44 and regulated Jun-N terminal kinase (JNK) in the reduction of the apoptosis of T cells.<sup>[<xref rid="j_rir-2023-0020_ref_065" ref-type="bibr">65</xref>,<xref rid="j_rir-2023-0020_ref_066" ref-type="bibr">66</xref>]</sup> hCDR1 treatment delayed the production of both anti-DNA antibodies and proteinuria, and increased the survival of lupus-prone mice by regulating B cell activating factor (BAFF).<sup>[<xref rid="j_rir-2023-0020_ref_067" ref-type="bibr">67</xref>]</sup> Additionally, hCDR1 improved cognitive behavior and brain pathology in lupus mice<sup>[<xref rid="j_rir-2023-0020_ref_068" ref-type="bibr">68</xref>]</sup> and downregulated the expression of the indoleamine 2, 3-dioxygenase (IDO) gene, which is increased in SLE patients.<sup>[<xref rid="j_rir-2023-0020_ref_047" ref-type="bibr">47</xref>]</sup></p><p>A phase II clinical trial with hCDR1 (Edratide) was conducted in 340 SLE patients and demonstrated that it was safe and well-tolerated. However, the co-primary endpoints of a reduction of SLE disease activity index (SLEDAI-2K) and adjusted mean SLEDAI (AMS) in patients compared with controls using a landmark analysis were not met.<sup>[<xref rid="j_rir-2023-0020_ref_069" ref-type="bibr">69</xref>]</sup> Secondary outcomes were improvement in the British Isles Lupus Assessment Group (BILAG) Responder Index and medicinal flare analysis. There was a positive trend in the Composite SLE Responder Index in the Intention-to-treat (ITT) cohort, and post-hoc analysis showed that the BILAG secondary endpoint was met for a number of subgroups dosing levels, including low or no steroids, seropositivity, and patients with 2 grade BILAG improvement.</p></sec><sec id="j_rir-2023-0020_s_005_s_003"><title>Nucleosomal Histone Peptides</title><p>Endogenous peptide epitopes of histones from nucleosomes induce immune tolerance and promote CD4<sup>+</sup> and CD8<sup>+</sup> T<sub>reg</sub> responses, and reduce lupus nephritis and B cell activation in (SWR x NZB) F1 (SNF1) mice,<sup>[<xref rid="j_rir-2023-0020_ref_070" ref-type="bibr">70</xref>, <xref rid="j_rir-2023-0020_ref_071" ref-type="bibr">71</xref>, <xref rid="j_rir-2023-0020_ref_072" ref-type="bibr">72</xref>]</sup> also blocking pathogenic autoimmunity in human SLE.<sup>[<xref rid="j_rir-2023-0020_ref_073" ref-type="bibr">73</xref>,<xref rid="j_rir-2023-0020_ref_074" ref-type="bibr">74</xref>]</sup></p><p>Other peptides derived from histone proteins have shown similar effects and have been investigated as therapeutic candidates in SLE,<sup>[<xref rid="j_rir-2023-0020_ref_075" ref-type="bibr">75</xref>, <xref rid="j_rir-2023-0020_ref_076" ref-type="bibr">76</xref>, <xref rid="j_rir-2023-0020_ref_077" ref-type="bibr">77</xref>]</sup> including the phosphorylated spliceosomal epitope peptide P140, which represses B cell differentiation and protects against murine lupus.<sup>[<xref rid="j_rir-2023-0020_ref_078" ref-type="bibr">78</xref>, <xref rid="j_rir-2023-0020_ref_079" ref-type="bibr">79</xref>, <xref rid="j_rir-2023-0020_ref_080" ref-type="bibr">80</xref>]</sup> Encouraging clinical trials indicate that it may improve clinical parameters in SLE patients.<sup>[<xref rid="j_rir-2023-0020_ref_015" ref-type="bibr">15</xref>,<xref rid="j_rir-2023-0020_ref_081" ref-type="bibr">81</xref>,<xref rid="j_rir-2023-0020_ref_082" ref-type="bibr">82</xref>]</sup></p></sec><sec id="j_rir-2023-0020_s_005_s_004"><title>DWEYS Peptide</title><p>DWEYS ((D/EWD/EYS/G)) peptide was identified using the mouse monoclonal anti-dsDNA R4A antibody.<sup>[<xref rid="j_rir-2023-0020_ref_083" ref-type="bibr">83</xref>, <xref rid="j_rir-2023-0020_ref_084" ref-type="bibr">84</xref>, <xref rid="j_rir-2023-0020_ref_085" ref-type="bibr">85</xref>, <xref rid="j_rir-2023-0020_ref_086" ref-type="bibr">86</xref>]</sup> It inhibits the R4A mAb from binding to dsDNA in animal models of lupus and SLE patients. It has been shown that the nephritogenic mouse monoclonal antibody R4A binds to a consensus pentapeptide sequence D/EWD/EYS/G (DWEYS), present in both NR2A and NR2B subunits of the mouse and human N-methyl-d-aspartate receptor (NMDAR).<sup>[<xref rid="j_rir-2023-0020_ref_084" ref-type="bibr">84</xref>,<xref rid="j_rir-2023-0020_ref_085" ref-type="bibr">85</xref>,<xref rid="j_rir-2023-0020_ref_087" ref-type="bibr">87</xref>]</sup> Anti-DWEYS and anti-dsDNA antibodies have cross-reactivity with NMDAR.<sup>[<xref rid="j_rir-2023-0020_ref_083" ref-type="bibr">83</xref>]</sup> Intravenous administration of the DWEYS peptide to gestating mice had protective effects on the fetal brains when exposed to toxic doses of anti-NMDAR antibodies.<sup>[<xref rid="j_rir-2023-0020_ref_088" ref-type="bibr">88</xref>]</sup> In <italic toggle="yes">ex vivo</italic> studies in lupus patients with anti-DNA antibodies and active lupus nephritis, the DWEYS peptide inhibited DNA binding.<sup>[<xref rid="j_rir-2023-0020_ref_088" ref-type="bibr">88</xref>, <xref rid="j_rir-2023-0020_ref_089" ref-type="bibr">89</xref>, <xref rid="j_rir-2023-0020_ref_090" ref-type="bibr">90</xref>]</sup> Furthermore, the peptide suppressed human autoreactive B cells and the production of anti-dsDNA antibodies <italic toggle="yes">in vitro</italic>.<sup>[<xref rid="j_rir-2023-0020_ref_090" ref-type="bibr">90</xref>]</sup></p></sec><sec id="j_rir-2023-0020_s_005_s_005"><title>FISLE-412</title><p>FISLE-412 is a small molecule peptidomimetic that can neutralize anti-dsDNA autoantibodies associated with SLE. FISLE-412 has shown effectiveness <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic>.<sup>[<xref rid="j_rir-2023-0020_ref_091" ref-type="bibr">91</xref>, <xref rid="j_rir-2023-0020_ref_092" ref-type="bibr">92</xref>, <xref rid="j_rir-2023-0020_ref_093" ref-type="bibr">93</xref>]</sup> It inhibits lupus autoantibody-mediated antigen recognition by human SLE patient serum and further prevents pathogenic interactions with tissue antigens.<sup>[<xref rid="j_rir-2023-0020_ref_091" ref-type="bibr">91</xref>]</sup> In addition, it suppresses pathogenic deposition of SLE autoantibodies into the kidney glomeruli, and blocks neurotoxicity <italic toggle="yes">in vivo</italic>.<sup>[<xref rid="j_rir-2023-0020_ref_091" ref-type="bibr">91</xref>]</sup> Based on its structure-activity relationships, several analogues of FISLE-412 have been developed and found to neutralize anti-lupus antibodies <italic toggle="yes">in vitro</italic> and <italic toggle="yes">ex vivo</italic>.<sup>[<xref rid="j_rir-2023-0020_ref_092" ref-type="bibr">92</xref>]</sup> FISLE-412 is well-tolerated and not immunogenic; as well as being stable, easily synthesized in high-throughput, and inexpensive to produce.<sup>[<xref rid="j_rir-2023-0020_ref_092" ref-type="bibr">92</xref>,<xref rid="j_rir-2023-0020_ref_094" ref-type="bibr">94</xref>]</sup></p></sec><sec id="j_rir-2023-0020_s_005_s_006"><title>ALW</title><p>ALW (ALWPPNLHAWVP) is a 12-mer peptide mimic identified from the four different types of murine monoclonal anti-DNA immunoglobulin G (IgG, including IgG1, IgG2a, IgG2b, and IgG3) by screening phage display libraries.<sup>[<xref rid="j_rir-2023-0020_ref_095" ref-type="bibr">95</xref>]</sup> ALW peptide exhibits isotype-dependent binding to anti-DNA antibodies in a sequence-specific manner. In addition, it markedly inhibits the binding of anti-DNA antibodies in human and mouse lupus sera to dsDNA and to laminin self-antigen. A protective effect of ALW peptide was demonstrated in MRL lymphoproliferation strain lupus mice, where it inhibited glomerular deposition of antibodies, reduced serum-anti-dsDNA antibodies, and improved overall renal pathology.<sup>[<xref rid="j_rir-2023-0020_ref_096" ref-type="bibr">96</xref>]</sup> Due to the absence of amino acids such as methionine, cysteine, and glutamine, ALW is physiologically stable and is resistant to peptide oxidation, cyclization, and degradation.<sup>[<xref rid="j_rir-2023-0020_ref_097" ref-type="bibr">97</xref>]</sup> It is nontoxic, non-immunogenic, and has a net neutral charge that reduces non-specific protein-protein interactions. As such, ALW or its analogues are seen as good potential novel candidate therapeutics in SLE.</p></sec><sec id="j_rir-2023-0020_s_005_s_007"><title>LJP-394 (Abetimus Sodium)</title><p>LJP-394 (Abetimus sodium) is a synthetic peptide developed to induce immune tolerance to double-stranded DNA (dsDNA), a key autoantigen in SLE.<sup>[<xref rid="j_rir-2023-0020_ref_098" ref-type="bibr">98</xref>]</sup> It is a tetrameric oligonucleotide conjugate that can reduce anti-dsDNA antibody levels, minimize nephritic flares,<sup>[<xref rid="j_rir-2023-0020_ref_098" ref-type="bibr">98</xref>]</sup> and act as a B cell tolerogen.<sup>[<xref rid="j_rir-2023-0020_ref_099" ref-type="bibr">99</xref>]</sup> It has been suggested that the relative affinity of dsDNA antibodies from SLE patients for LJP-394 may impact their responses to the drug, and patients with high-affinity antibodies to LJP-394 experience a reduction in affinity after four months of weekly treatment.<sup>[<xref rid="j_rir-2023-0020_ref_100" ref-type="bibr">100</xref>]</sup></p><p>LJP-394 has been evaluated in 14 clinical trials<sup>[<xref rid="j_rir-2023-0020_ref_101" ref-type="bibr">101</xref>]</sup> and has shown to be safe and reduce circulating anti-dsDNA antibodies and disease activity in patients with active SLE. However, two pivotal trials failed to meet the primary endpoint of a statistically significant prolongation in the time to renal flare.<sup>[<xref rid="j_rir-2023-0020_ref_098" ref-type="bibr">98</xref>,<xref rid="j_rir-2023-0020_ref_102" ref-type="bibr">102</xref>]</sup> In another clinical trial, a dosage of 100 mg/week of LJP-394 significantly reduced anti-dsDNA antibody levels but did not significantly prolong the time to renal flare compared to placebo. Nonetheless, several positive trends in endpoints were observed in the treated group,<sup>[<xref rid="j_rir-2023-0020_ref_103" ref-type="bibr">103</xref>]</sup> leading to wonder how to improve targeting of this agent to the most suitable SLE patients.</p></sec></sec><sec id="j_rir-2023-0020_s_006"><title>Use of Nanotechnology in Peptide-Induced Tolerance in SLE</title><p>Nanotechnology is a promising field for the development of new therapeutics including in autoimmune rheumatic diseases.<sup>[<xref rid="j_rir-2023-0020_ref_104" ref-type="bibr">104</xref>, <xref rid="j_rir-2023-0020_ref_105" ref-type="bibr">105</xref>, <xref rid="j_rir-2023-0020_ref_106" ref-type="bibr">106</xref>]</sup> In SLE, nanotechnology-based strategies have been developed to induce immune tolerance to self-antigens<sup>[<xref rid="j_rir-2023-0020_ref_107" ref-type="bibr">107</xref>]</sup> and to deliver peptides that modulate the immune response.<sup>[<xref rid="j_rir-2023-0020_ref_108" ref-type="bibr">108</xref>]</sup></p><p>Nanoparticles offers several advantages over traditional drug delivery systems, including improved pharmacokinetics, enhanced stability, and reduced toxicity.<sup>[<xref rid="j_rir-2023-0020_ref_105" ref-type="bibr">105</xref>]</sup> In SLE, nanoparticles have been used to deliver lupus-specific peptides, selectively targeting autoimmune B cells, and inducing immune tolerance. For instance, poly-(lactic-co-glycolic acid) (PLGA) nanoparticles loaded with a lupus-specific peptide (P140) have demonstrated efficacy in reducing autoantibody production and renal damage in lupus-prone mice.<sup>[<xref rid="j_rir-2023-0020_ref_109" ref-type="bibr">109</xref>]</sup> Another study utilized T cell targeted PLGA-nanoparticles encapsulating IL-2 and TGF-&#946; resulting in the expansion of both CD4<sup>+</sup> and CD8<sup>+</sup> T<sub>regs</sub>
<italic toggle="yes">in vivo</italic> and suppression of murine lupus.<sup>[<xref rid="j_rir-2023-0020_ref_110" ref-type="bibr">110</xref>]</sup> Additionally, the delivery of a calcium/calmodulin-dependent protein kinase-IV (CAMK4) inhibitor via nanoparticles ameliorated murine SLE.<sup>[<xref rid="j_rir-2023-0020_ref_111" ref-type="bibr">111</xref>,<xref rid="j_rir-2023-0020_ref_112" ref-type="bibr">112</xref>]</sup> Furthermore, microRNA125a-loaded nanoparticles have also been found to restore homeostasis and ameliorate murine lupus by regulating the balance between T effector cells and T<sub>regs.</sub><sup>[<xref rid="j_rir-2023-0020_ref_113" ref-type="bibr">113</xref>]</sup></p><p>Apart from delivering lupus-specific peptides, nanoparticles can be engineered to target specific immune cells and tissues. For example, mesoporous silica nanoparticles (MSNs) functionalized with lupus-specific peptides and antibodies have been developed to selectively target immune cells and tissues.<sup>[<xref rid="j_rir-2023-0020_ref_114" ref-type="bibr">114</xref>, <xref rid="j_rir-2023-0020_ref_115" ref-type="bibr">115</xref>, <xref rid="j_rir-2023-0020_ref_116" ref-type="bibr">116</xref>, <xref rid="j_rir-2023-0020_ref_117" ref-type="bibr">117</xref>]</sup> Similarly, magnetic nanoparticles (MNPs) coated with a lupus-specific peptide have been shown to selectively target lupus B cells and induce immune tolerance.<sup>[<xref rid="j_rir-2023-0020_ref_110" ref-type="bibr">110</xref>,<xref rid="j_rir-2023-0020_ref_118" ref-type="bibr">118</xref>,<xref rid="j_rir-2023-0020_ref_119" ref-type="bibr">119</xref>]</sup> Furthermore, nanotechnology-based strategies enable the delivery of immunomodulatory agents such as immunosuppressants to target specific immune cells and tissues. For instance, PLGA nanoparticles loaded with rapamycin, an immunosuppressant, have shown effectiveness in reducing autoantibody production and renal damage in lupus-prone mice.<sup>[<xref rid="j_rir-2023-0020_ref_120" ref-type="bibr">120</xref>,<xref rid="j_rir-2023-0020_ref_121" ref-type="bibr">121</xref>]</sup> Also, dendrimers loaded with anti-inflammatory IL-10 reduce disease activity in mice.<sup>[<xref rid="j_rir-2023-0020_ref_122" ref-type="bibr">122</xref>, <xref rid="j_rir-2023-0020_ref_123" ref-type="bibr">123</xref>, <xref rid="j_rir-2023-0020_ref_124" ref-type="bibr">124</xref>]</sup></p></sec><sec id="j_rir-2023-0020_s_007"><title>Conclusions and Future Perspectives</title><p>Peptide-based therapies for lupus have shown great promise in preclinical but clinical studies have been so far rather limited. This mandates additional clinical studies to better elucidate the potential of peptide-based therapies in SLE. In clinical studies, peptides have demonstrated safety and tolerability; however, only variable efficacy has been demonstrated in reducing disease activity in SLE patients, possibly due to trial design that cannot preselect those patients that might benefit the most from peptide immunotherapy. Of note, peptides have nonetheless consistently shown the potential to induce immune tolerance, which is dysregulated in SLE patients. Peptide-based therapies have also shown the potential to selectively target specific immune cell populations, either B cell or T cell populations.</p><p>Peptides such as ALW and FISLE-412 have demonstrated the ability to neutralize lupus autoantibodies and prevent their pathogenic interactions with tissue antigens. More recently, the encapsulation of peptides in nanocarriers is leading to agents that can have improved pharmacokinetics, biodistri-bution, and bioavailability, as well as enhanced targe specificity. Nanoparticles can also help to reduce toxicity.</p><p>Despite this all, there are still challenges that need to be addressed. One is identifying the optimal peptide sequences and dosage to achieve the most effective outcomes. Another challenge is to develop the proper biomarkers to monitor response and predict treatment outcomes. One important consideration is that combination therapies that involve peptides and other immunomodulatory agents can developed but have so far not been tested.</p><p>To conclude, peptide-based therapies can promote immune tolerance and have shown great potential in reducing disease activity in lupus patients. With further research, new technologies such as nanotechnology and more information on how to better refine what we know for better clinical trials, peptide-based therapies could become a new avenue of treatment for SLE.</p></sec></body><back><ack id="j_rir-2023-0020_ack_001"><title>Acknowledgments</title><p>We acknowledge Dr. David D. Brand, Ph.D. of VA Medical Center, Memphis, University of Tennessee, for his intellectual insights, help in figure drawing, and reading the manuscript.</p></ack><fn-group><fn fn-type="other" id="j_rir-2023-0020_fn_101"><p>
<bold>Author Contributions</bold>
</p><p>RPS conceptualized the article, reviewed the literature and wrote the first draft of the manuscript. DSB, SSS and BH edited the manuscript and made intellectual contributions. All authors contributed to the work and approved it for publication.</p></fn><fn fn-type="other" id="j_rir-2023-0020_fn_102"><p>
<bold>Informed Consent</bold>
</p><p>Not applicable.</p></fn><fn fn-type="other" id="j_rir-2023-0020_fn_103"><p>
<bold>Ethics Approval</bold>
</p><p>Not applicable.</p></fn><fn fn-type="COI-statement" id="j_rir-2023-0020_fn_001"><p>
<bold>Conflict of Interest</bold>
</p><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></fn><fn fn-type="other" id="j_rir-2023-0020_fn_104"><p>
<bold>Data Availability Statement</bold>
</p><p>Not applicable.</p></fn></fn-group><ref-list><title>References</title><ref id="j_rir-2023-0020_ref_001"><label>[1]</label><element-citation publication-type="journal"><name name-style="western"><surname>Bultink</surname><given-names>IEM</given-names></name><name name-style="western"><surname>de Vries</surname><given-names>F</given-names></name><name name-style="western"><surname>van Vollenhoven</surname><given-names>RF</given-names></name><comment>et al</comment><article-title>Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls</article-title><source>Rheumatology (Oxford)</source><year>2021</year><volume>60</volume><fpage>207</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">32653901</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/rheumatology/keaa267</pub-id><pub-id pub-id-type="pmcid">PMC8312724</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_002"><label>[2]</label><element-citation publication-type="journal"><name name-style="western"><surname>Lau</surname><given-names>CS</given-names></name><name name-style="western"><surname>Mak</surname><given-names>A</given-names></name><article-title>The socioeconomic burden of SLE</article-title><source>Nat Rev Rheumatol</source><year>2009</year><volume>5</volume><fpage>400</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">19506585</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrrheum.2009.106</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_003"><label>[3]</label><element-citation publication-type="journal"><name name-style="western"><surname>L&#248;ppenthin</surname><given-names>K</given-names></name><name name-style="western"><surname>Esbensen</surname><given-names>BA</given-names></name><name name-style="western"><surname>&#216;stergaard</surname><given-names>M</given-names></name><comment>et al</comment><article-title>Morbidity and mortality in patients with rheumatoid arthritis compared with an age- and sex-matched control population: A nationwide register study</article-title><source>J Comorb</source><year>2019</year><volume>9</volume><fpage>2235042</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2235042X19853484</pub-id><pub-id pub-id-type="pmcid">PMC6547169</pub-id><pub-id pub-id-type="pmid">31211114</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_004"><label>[4]</label><element-citation publication-type="journal"><source>Tsokos GC. Systemic lupus erythematosus. N Engl J Med</source><year>2011</year><volume>365</volume><fpage>2110</fpage><lpage>2121</lpage><pub-id pub-id-type="pmid">22129255</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMra1100359</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_005"><label>[5]</label><element-citation publication-type="journal"><name name-style="western"><surname>Guillermo</surname><given-names>Ruiz-Irastorza</given-names></name><name name-style="western"><surname>George</surname><given-names>Bertsias</given-names></name><article-title>Treating systemic lupus erythematosus in the 21st century</article-title><source>new drugs and new perspectives on old drugs. Rheumatology (Oxford)</source><year>2020</year><volume>59</volume><fpage>v69</fpage><lpage>v81</lpage><comment>DOI</comment><pub-id pub-id-type="doi">10.1093/rheumatology/keaa403]</pub-id><pub-id pub-id-type="pmid">33280011</pub-id><pub-id pub-id-type="pmcid">PMC7719039</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_006"><label>[6]</label><element-citation publication-type="journal"><name name-style="western"><surname>Broen</surname><given-names>JCA</given-names></name><name name-style="western"><surname>van</surname><given-names>Laar JM</given-names></name><article-title>Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology</article-title><source>Nat Rev Rheumatol</source><year>2020</year><volume>16</volume><fpage>167</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">32055040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41584-020-0374-8</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_007"><label>[7]</label><element-citation publication-type="journal"><name name-style="western"><surname>Burmester</surname><given-names>GR</given-names></name><name name-style="western"><surname>Pope</surname><given-names>JE</given-names></name><article-title>Novel treatment strategies in rheumatoid arthritis</article-title><source>Lancet</source><year>2017</year><volume>389</volume><fpage>2338</fpage><lpage>2348</lpage><pub-id pub-id-type="pmid">28612748</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(17)31491-5</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_008"><label>[8]</label><element-citation publication-type="journal"><name name-style="western"><surname>Williams</surname><given-names>EL</given-names></name><name name-style="western"><surname>Gadola</surname><given-names>S</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>CJ</given-names></name><article-title>Anti-TNF-induced lupus</article-title><source>Rheumatology (Oxford)</source><year>2009</year><volume>48</volume><issue>7</issue><fpage>716</fpage><lpage>720</lpage><pub-id pub-id-type="pmid">19416947</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/rheumatology/kep080</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_009"><label>[9]</label><element-citation publication-type="journal"><name name-style="western"><surname>Singh</surname><given-names>RP</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>BH</given-names></name><name name-style="western"><surname>Bischoff</surname><given-names>DS</given-names></name><article-title>Effects of Peptide-Induced Immune Tolerance on Murine Lupus</article-title><source>Front Immunol</source><year>2021</year><volume>12</volume><fpage>662901</fpage><pub-id pub-id-type="pmid">34093553</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2021.662901</pub-id><pub-id pub-id-type="pmcid">PMC8171184</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_010"><label>[10]</label><element-citation publication-type="journal"><name name-style="western"><surname>Singh</surname><given-names>RP</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>BH</given-names></name><name name-style="western"><surname>Bischoff</surname><given-names>DS. Cellular</given-names></name><name name-style="western"><surname>Molecular</surname><given-names>Phenotypes</given-names></name><article-title>of pConsensus Peptide (pCons) Induced CD8+ and CD4+ Regulatory T Cells in Lupus</article-title><source>Front Immunol</source><year>2021</year><volume>12</volume><fpage>718359</fpage><pub-id pub-id-type="pmid">34867947</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2021.718359</pub-id><pub-id pub-id-type="pmcid">PMC8640085</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_011"><label>[11]</label><element-citation publication-type="journal"><name name-style="western"><surname>Yu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shi</surname><given-names>FD</given-names></name><comment>et al</comment><article-title>Tolerance induced by anti-DNA Ig peptide in (NZB&#215;NZW)F1 lupus mice impinges on the resistance of effector T cells to suppression by regulatory T cells</article-title><source>Clin Immunol</source><year>2012</year><volume>142</volume><fpage>291</fpage><lpage>295</lpage><pub-id pub-id-type="pmid">22137928</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clim.2011.11.004</pub-id><pub-id pub-id-type="pmcid">PMC3288892</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_012"><label>[12]</label><element-citation publication-type="journal"><name name-style="western"><surname>Black</surname><given-names>M</given-names></name><name name-style="western"><surname>Trent</surname><given-names>A</given-names></name><name name-style="western"><surname>Tirrell</surname><given-names>M</given-names></name><comment>et al</comment><article-title>Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists</article-title><source>Expert Rev Vaccines</source><year>2010</year><volume>9</volume><fpage>157</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">20109027</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/erv.09.160</pub-id><pub-id pub-id-type="pmcid">PMC2837080</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_013"><label>[13]</label><element-citation publication-type="journal"><name name-style="western"><surname>Gokhale</surname><given-names>AS</given-names></name><name name-style="western"><surname>Satyanarayanajois</surname><given-names>S. Peptides</given-names></name><comment>and</comment><article-title>peptidomimetics as immunomodulators</article-title><source>Immunotherapy</source><year>2014</year><volume>6</volume><fpage>755</fpage><lpage>774</lpage><pub-id pub-id-type="pmid">25186605</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/imt.14.37</pub-id><pub-id pub-id-type="pmcid">PMC4201125</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_014"><label>[14]</label><element-citation publication-type="journal"><name name-style="western"><surname>Shoenfeld</surname><given-names>Y</given-names></name><article-title>Anti-DNA idiotypes: from induction of disease to novel therapeutical approaches</article-title><source>Immunol Lett</source><year>2005</year><volume>100</volume><fpage>73</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">16245396</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.imlet.2005.06.015</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_015"><label>[15]</label><element-citation publication-type="journal"><name name-style="western"><surname>Schall</surname><given-names>N</given-names></name><name name-style="western"><surname>Muller</surname><given-names>S</given-names></name><article-title>Resetting the autoreactive immune system with a therapeutic peptide in lupus</article-title><source>Lupus</source><year>2015</year><volume>24</volume><fpage>412</fpage><lpage>418</lpage><comment>DOI</comment><pub-id pub-id-type="doi">10.1177/0961203314556138]</pub-id><pub-id pub-id-type="pmid">25801884</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_016"><label>[16]</label><element-citation publication-type="journal"><name name-style="western"><surname>Favoino</surname><given-names>E</given-names></name><name name-style="western"><surname>Prete</surname><given-names>M</given-names></name><name name-style="western"><surname>Marzullo</surname><given-names>A</given-names></name><comment>et al</comment><article-title>CD20-Mimotope Peptide Active Immunotherapy in Systemic Lupus Erythematosus and a Reappraisal of Vaccination Strategies in Rheumatic Diseases</article-title><source>Clin Rev Allergy Immunol</source><year>2017</year><volume>52</volume><fpage>217</fpage><lpage>233</lpage><pub-id pub-id-type="pmid">27216429</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12016-016-8551-x</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_017"><label>[17]</label><element-citation publication-type="journal"><name name-style="western"><surname>Rosenthal</surname><given-names>KS</given-names></name><name name-style="western"><surname>Mikecz</surname><given-names>K</given-names></name><comment>Steiner HL 3rd, et al</comment><article-title>Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis</article-title><source>Expert Rev Vaccines</source><year>2015</year><volume>14</volume><fpage>891</fpage><lpage>908</lpage><pub-id pub-id-type="pmid">25787143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/14760584.2015.1026330</pub-id><pub-id pub-id-type="pmcid">PMC4786169</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_018"><label>[18]</label><element-citation publication-type="journal"><name name-style="western"><surname>Mikecz</surname><given-names>K</given-names></name><name name-style="western"><surname>Glant</surname><given-names>TT</given-names></name><name name-style="western"><surname>Markovics</surname><given-names>A</given-names></name><comment>et al</comment><article-title>An epitope-specific DerG-PG70 LEAPS vaccine modulates T cell responses and suppresses arthritis progression in two related murine models of rheumatoid arthritis</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>4048</fpage><lpage>4056</lpage><pub-id pub-id-type="pmid">28583308</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2017.05.009</pub-id><pub-id pub-id-type="pmcid">PMC5568759</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_019"><label>[19]</label><element-citation publication-type="journal"><name name-style="western"><surname>Smith</surname><given-names>EL</given-names></name><name name-style="western"><surname>Peakman</surname><given-names>M</given-names></name><article-title>Peptide Immunotherapy for Type 1 Diabetes-Clinical Advances</article-title><source>Front Immunol</source><year>2018</year><volume>9</volume><fpage>392</fpage><pub-id pub-id-type="pmid">29541078</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2018.00392</pub-id><pub-id pub-id-type="pmcid">PMC5836708</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_020"><label>[20]</label><element-citation publication-type="journal"><name name-style="western"><surname>Arif</surname><given-names>S</given-names></name><name name-style="western"><surname>Gomez-Tourino</surname><given-names>I</given-names></name><name name-style="western"><surname>Kamra</surname><given-names>Y</given-names></name><comment>et al</comment><article-title>GAD-alum immunotherapy in type 1 diabetes expands bifunctional Th1/Th2 auto-reactive CD4 T cells</article-title><source>Diabetologia</source><year>2020</year><volume>63</volume><fpage>1186</fpage><lpage>1198</lpage><pub-id pub-id-type="pmid">32248243</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00125-020-05130-7</pub-id><pub-id pub-id-type="pmcid">PMC7228993</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_021"><label>[21]</label><element-citation publication-type="journal"><name name-style="western"><surname>Zorzella-Pezavento</surname><given-names>SFG</given-names></name><name name-style="western"><surname>Mimura</surname><given-names>LAN</given-names></name><name name-style="western"><surname>Fraga-Silva</surname><given-names>TFC</given-names></name><comment>et al</comment><article-title>Experimental Autoimmune Encephalomyelitis Is Successfully Controlled by Epicutaneous Administration of MOG Plus Vitamin D Analog</article-title><source>Front Immunol</source><year>2017</year><volume>8</volume><fpage>1198</fpage><pub-id pub-id-type="pmid">29085356</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2017.01198</pub-id><pub-id pub-id-type="pmcid">PMC5650696</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_022"><label>[22]</label><element-citation publication-type="journal"><name name-style="western"><surname>Hahn</surname><given-names>BH</given-names></name><name name-style="western"><surname>Singh</surname><given-names>RP</given-names></name><name name-style="western"><surname>La</surname><given-names>Cava A</given-names></name><comment>et al</comment><article-title>Tolerogenic treatment of lupus mice with consensus peptide induces Foxp3-expressing, apoptosis-resistant, TGFbeta-secreting CD8+ T cell suppressors</article-title><source>J Immunol</source><year>2005</year><volume>175</volume><fpage>7728</fpage><lpage>7737</lpage><pub-id pub-id-type="pmid">16301683</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.175.11.7728</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_023"><label>[23]</label><element-citation publication-type="journal"><name name-style="western"><surname>La</surname><given-names>Cava A</given-names></name><name name-style="western"><surname>Fang</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Singh</surname><given-names>RP</given-names></name><comment>et al</comment><article-title>Manipulation of immune regulation in systemic lupus erythematosus</article-title><source>Autoimmun Rev</source><year>2005</year><volume>4</volume><fpage>515</fpage><lpage>519</lpage><pub-id pub-id-type="pmid">16214088</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.autrev.2005.04.008</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_024"><label>[24]</label><element-citation publication-type="journal"><name name-style="western"><surname>Mozes</surname><given-names>E</given-names></name><name name-style="western"><surname>Sharabi</surname><given-names>A</given-names></name><article-title>A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosus</article-title><source>Autoimmun Rev</source><year>2010</year><volume>10</volume><fpage>22</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">20659591</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.autrev.2010.07.004</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_025"><label>[25]</label><element-citation publication-type="journal"><name name-style="western"><surname>Sharabi</surname><given-names>A</given-names></name><name name-style="western"><surname>Haviv</surname><given-names>A</given-names></name><name name-style="western"><surname>Zinger</surname><given-names>H</given-names></name><comment>et al</comment><article-title>Amelioration of murine lupus by a peptide, based on the complementarity determining region-1 of an autoantibody as compared to dexamethasone: different effects on cytokines and apoptosis</article-title><source>Clin Immunol</source><year>2006</year><volume>119</volume><fpage>146</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">16503419</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clim.2006.01.007</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_026"><label>[26]</label><element-citation publication-type="journal"><name name-style="western"><surname>Singh</surname><given-names>RP</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>BH</given-names></name><name name-style="western"><surname>La</surname><given-names>Cava A</given-names></name><article-title>Tuning immune suppression in systemic autoimmunity with self-derived peptides</article-title><source>Inflamm Allergy Drug Targets</source><year>2008</year><volume>7</volume><fpage>253</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">19075790</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/187152808786848423</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_027"><label>[27]</label><element-citation publication-type="journal"><name name-style="western"><surname>Singh</surname><given-names>RP</given-names></name><name name-style="western"><surname>La</surname><given-names>Cava A</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>BH</given-names></name><article-title>pConsensus peptide induces tolerogenic CD8+ T cells in lupus-prone (NZB x NZW)F1 mice by differentially regulating Foxp3 and PD1 molecules</article-title><source>J Immunol</source><year>2008</year><volume>180</volume><fpage>2069</fpage><lpage>2080</lpage><pub-id pub-id-type="pmid">18250412</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.180.4.2069</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_028"><label>[28]</label><element-citation publication-type="journal"><name name-style="western"><surname>Singh</surname><given-names>RP</given-names></name><name name-style="western"><surname>La</surname><given-names>Cava A</given-names></name><name name-style="western"><surname>Wong</surname><given-names>M</given-names></name><comment>et al</comment><article-title>CD8+ T cell-mediated suppression of autoimmunity in a murine lupus model of peptide-induced immune tolerance depends on Foxp3 expression</article-title><source>J Immunol</source><year>2007</year><volume>178</volume><fpage>7649</fpage><lpage>7657</lpage><pub-id pub-id-type="pmid">17548601</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.178.12.7649</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_029"><label>[29]</label><element-citation publication-type="journal"><name name-style="western"><surname>Burkhardt</surname><given-names>H</given-names></name><name name-style="western"><surname>Koller</surname><given-names>T</given-names></name><name name-style="western"><surname>Engstr&#246;m</surname><given-names>A</given-names></name><comment>et al</comment><article-title>Epitope-specific recognition of type II collagen by rheumatoid arthritis antibodies is shared with recognition by antibodies that are arthritogenic in collagen-induced arthritis in the mouse</article-title><source>Arthritis Rheum</source><year>2002</year><volume>46</volume><fpage>2339</fpage><lpage>2348</lpage><pub-id pub-id-type="pmid">12355481</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/art.10472</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_030"><label>[30]</label><element-citation publication-type="journal"><name name-style="western"><surname>Daveson</surname><given-names>AJM</given-names></name><name name-style="western"><surname>Ee</surname><given-names>HC</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>JM</given-names></name><comment>et al</comment><article-title>Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study</article-title><source>EBioMedicine</source><year>2017</year><volume>26</volume><fpage>78</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">29191561</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2017.11.018</pub-id><pub-id pub-id-type="pmcid">PMC5832635</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_031"><label>[31]</label><element-citation publication-type="journal"><name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ren</surname><given-names>J</given-names></name><name name-style="western"><surname>Dai</surname><given-names>C</given-names></name><comment>et al</comment><article-title>Nature of T cell epitopes in lupus antigens and HLA-DR determines autoantibody initiation and diversification</article-title><source>Ann Rheum Dis</source><year>2019</year><volume>78</volume><fpage>380</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">30254034</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/annrheumdis-2018-214125</pub-id><pub-id pub-id-type="pmcid">PMC6377330</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_032"><label>[32]</label><element-citation publication-type="journal"><name name-style="western"><surname>Monneaux</surname><given-names>F</given-names></name><name name-style="western"><surname>Muller</surname><given-names>S</given-names></name><article-title>Peptide-based immunotherapy of systemic lupus erythematosus</article-title><source>Autoimmun Rev</source><year>2004</year><volume>3</volume><fpage>16</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">14871645</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1568-9972(03)00061-2</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_033"><label>[33]</label><element-citation publication-type="journal"><name name-style="western"><surname>Datta</surname><given-names>SK</given-names></name><article-title>Harnessing Tolerogenic Histone Peptide Epitopes From Nucleosomes for Selective Down-Regulation of Pathogenic Autoimmune Response in Lupus (Past, Present, and Future)</article-title><source>Front Immunol</source><year>2021</year><volume>12</volume><fpage>629807</fpage><pub-id pub-id-type="pmid">33936042</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2021.629807</pub-id><pub-id pub-id-type="pmcid">PMC8080879</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_034"><label>[34]</label><element-citation publication-type="journal"><name name-style="western"><surname>J&#252;rgen</surname><given-names>W Dieker</given-names></name><name name-style="western"><surname>Yong-Jiang</surname><given-names>Sun</given-names></name><name name-style="western"><surname>Cor</surname><given-names>W Jacobs</given-names></name><comment>et al</comment><article-title>Mimotopes for lupus-derived anti-DNA and nucleosome-specific autoantibodies selected from random peptide phage display libraries: facts and follies</article-title><source>J Immunol Methods</source><year>2005</year><volume>296</volume><fpage>83</fpage><lpage>93</lpage><comment>DOI</comment><pub-id pub-id-type="doi">10.1016/j.jim.2004.10.010]</pub-id><pub-id pub-id-type="pmid">15680153</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_035"><label>[35]</label><element-citation publication-type="journal"><name name-style="western"><surname>Sibille</surname><given-names>P</given-names></name><name name-style="western"><surname>Ternynck</surname><given-names>T</given-names></name><name name-style="western"><surname>Nato</surname><given-names>F</given-names></name><comment>et al</comment><article-title>Mimotopes of polyreactive anti-DNA antibodies identified using phage-display peptide libraries</article-title><source>Eur J Immunol</source><year>1997</year><volume>27</volume><fpage>1221</fpage><lpage>1228</lpage><pub-id pub-id-type="pmid">9174614</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/eji.1830270525</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_036"><label>[36]</label><element-citation publication-type="journal"><name name-style="western"><surname>Slansky</surname><given-names>JE</given-names></name><name name-style="western"><surname>Nakayama</surname><given-names>M</given-names></name><article-title>Peptide mimotopes alter T cell function in cancer and autoimmunity</article-title><source>Semin Immunol</source><year>2020</year><volume>47</volume><fpage>101395</fpage><pub-id pub-id-type="pmid">32205022</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.smim.2020.101395</pub-id><pub-id pub-id-type="pmcid">PMC7160047</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_037"><label>[37]</label><element-citation publication-type="journal"><name name-style="western"><surname>Wang</surname><given-names>B</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Q</given-names></name><comment>et al</comment><article-title>Peptide-Based Vaccination Therapy for Rheumatic Diseases</article-title><source>J Immunol Res</source><year>2020</year><volume>2020</volume><fpage>8060375</fpage><pub-id pub-id-type="pmid">32258176</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2020/8060375</pub-id><pub-id pub-id-type="pmcid">PMC7104265</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_038"><label>[38]</label><element-citation publication-type="journal"><name name-style="western"><surname>Dinarello</surname><given-names>CA</given-names></name><article-title>Anti-inflammatory Agents: Present and Future</article-title><source>Cell</source><year>2010</year><volume>140</volume><fpage>935</fpage><lpage>950</lpage><pub-id pub-id-type="pmid">20303881</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2010.02.043</pub-id><pub-id pub-id-type="pmcid">PMC3752337</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_039"><label>[39]</label><element-citation publication-type="journal"><name name-style="western"><surname>La</surname><given-names>Cava A</given-names></name><article-title>Targeting the BLyS-APRIL signaling pathway in SLE</article-title><source>Clin Immunol</source><year>2013</year><volume>148</volume><fpage>322</fpage><lpage>327</lpage><pub-id pub-id-type="pmid">23269199</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clim.2012.11.010</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_040"><label>[40]</label><element-citation publication-type="journal"><name name-style="western"><surname>Semerano</surname><given-names>L</given-names></name><name name-style="western"><surname>Assier</surname><given-names>E</given-names></name><name name-style="western"><surname>Boissier</surname><given-names>MC</given-names></name><article-title>Anti-cytokine vaccination: a new biotherapy of autoimmunity?</article-title><source>Autoimmun Rev</source><year>2012</year><volume>11</volume><fpage>785</fpage><lpage>786</lpage><pub-id pub-id-type="pmid">22349621</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.autrev.2012.02.003</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_041"><label>[41]</label><element-citation publication-type="journal"><name name-style="western"><surname>Zagury</surname><given-names>D</given-names></name><name name-style="western"><surname>Burny</surname><given-names>A</given-names></name><name name-style="western"><surname>Gallo</surname><given-names>RC</given-names></name><article-title>Toward a new generation of vaccines: the anti-cytokine therapeutic vaccines</article-title><source>Proc Natl Acad Sci U S A</source><year>2001</year><volume>98</volume><fpage>8024</fpage><lpage>8029</lpage><pub-id pub-id-type="pmid">11438746</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.141224798</pub-id><pub-id pub-id-type="pmcid">PMC35461</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_042"><label>[42]</label><element-citation publication-type="journal"><name name-style="western"><surname>Amarilyo</surname><given-names>G</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>B</given-names></name><name name-style="western"><surname>La</surname><given-names>Cava A</given-names></name><article-title>Preclinical studies with synthetic peptides in systemic lupus erythematosus</article-title><source>Front Biosci (Landmark Ed)</source><year>2012</year><volume>17</volume><fpage>1940</fpage><lpage>1947</lpage><pub-id pub-id-type="pmid">22201847</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2741/4030</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_043"><label>[43]</label><element-citation publication-type="journal"><name name-style="western"><surname>Hahn</surname><given-names>BH</given-names></name><name name-style="western"><surname>Singh</surname><given-names>RR</given-names></name><name name-style="western"><surname>Wong</surname><given-names>WK</given-names></name><comment>et al</comment><article-title>Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus</article-title><source>Arthritis Rheum</source><year>2001</year><volume>44</volume><fpage>432</fpage><lpage>441</lpage><pub-id pub-id-type="pmid">11229475</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1529-0131(200102)44:2&lt;432::AID-ANR62&gt;3.0.CO;2-S</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_044"><label>[44]</label><element-citation publication-type="journal"><name name-style="western"><surname>Schall</surname><given-names>N</given-names></name><name name-style="western"><surname>Page</surname><given-names>N</given-names></name><name name-style="western"><surname>Macri</surname><given-names>C</given-names></name><comment>et al</comment><article-title>Peptide-based approaches to treat lupus and other autoimmune diseases</article-title><source>J Autoimmun</source><year>2012</year><volume>39</volume><fpage>143</fpage><lpage>153</lpage><pub-id pub-id-type="pmid">22727561</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaut.2012.05.016</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_045"><label>[45]</label><element-citation publication-type="journal"><name name-style="western"><surname>Singh</surname><given-names>RR</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>V</given-names></name><name name-style="western"><surname>Ebling</surname><given-names>FM</given-names></name><comment>et al</comment><article-title>T cell determinants from autoantibodies to DNA can upregulate autoimmunity in murine systemic lupus erythematosus</article-title><source>J Exp Med</source><year>1995</year><volume>181</volume><fpage>2017</fpage><lpage>2027</lpage><pub-id pub-id-type="pmid">7539036</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.181.6.2017</pub-id><pub-id pub-id-type="pmcid">PMC2192064</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_046"><label>[46]</label><element-citation publication-type="journal"><name name-style="western"><surname>Spiering</surname><given-names>R</given-names></name><name name-style="western"><surname>Margry</surname><given-names>B</given-names></name><name name-style="western"><surname>Keijzer</surname><given-names>C</given-names></name><comment>et al</comment><article-title>DEC205+ Dendritic Cell-Targeted Tolerogenic Vaccination Promotes Immune Tolerance in Experimental Autoimmune Arthritis</article-title><source>J Immunol</source><year>2015</year><volume>194</volume><fpage>4804</fpage><lpage>4813</lpage><pub-id pub-id-type="pmid">25862815</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1400986</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_047"><label>[47]</label><element-citation publication-type="journal"><name name-style="western"><surname>Sthoeger</surname><given-names>Z</given-names></name><name name-style="western"><surname>Sharabi</surname><given-names>A</given-names></name><name name-style="western"><surname>Zinger</surname><given-names>H</given-names></name><comment>et al</comment><article-title>Indoleamine-2,3-dioxygenase in murine and human systemic lupus erythematosus: Down-regulation by the tolerogeneic peptide hCDR1</article-title><source>Clin Immunol</source><year>2018</year><volume>197</volume><fpage>34</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">30170030</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clim.2018.08.012</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_048"><label>[48]</label><element-citation publication-type="journal"><name name-style="western"><surname>Koriyama</surname><given-names>H</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nakagami</surname><given-names>H</given-names></name><comment>et al</comment><article-title>Development of an IL-17A DNA Vaccine to Treat Systemic Lupus Erythematosus in Mice</article-title><source>Vaccines (Basel)</source><year>2020</year><volume>8</volume><fpage>83</fpage><pub-id pub-id-type="pmid">32059488</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines8010083</pub-id><pub-id pub-id-type="pmcid">PMC7157613</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_049"><label>[49]</label><element-citation publication-type="journal"><name name-style="western"><surname>O&#8217;Connor</surname><given-names>RA</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Blumerman</surname><given-names>S</given-names></name><comment>et al</comment><article-title>Adjuvant immunotherapy of experimental autoimmune encephalomyelitis: immature myeloid cells expressing CXCL10 and CXCL16 attract CXCR3+CXCR6+ and myelin-specific T cells to the draining lymph nodes rather than the central nervous system</article-title><source>J Immunol</source><year>2012</year><volume>188</volume><fpage>2093</fpage><lpage>2101</lpage><pub-id pub-id-type="pmid">22287719</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1101118</pub-id><pub-id pub-id-type="pmcid">PMC3987917</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_050"><label>[50]</label><element-citation publication-type="journal"><name name-style="western"><surname>Lamontain</surname><given-names>V</given-names></name><name name-style="western"><surname>Schmid</surname><given-names>T</given-names></name><name name-style="western"><surname>Weber-Steffens</surname><given-names>D</given-names></name><comment>et al</comment><article-title>Stimulation of TNF receptor type 2 expands regulatory T cells and ameliorates established collagen-induced arthritis in mice</article-title><source>Cell Mol Immunol</source><year>2019</year><volume>16</volume><fpage>65</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">29375132</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/cmi.2017.138</pub-id><pub-id pub-id-type="pmcid">PMC6318277</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_051"><label>[51]</label><element-citation publication-type="journal"><name name-style="western"><surname>Mark</surname><given-names>Farrugia</given-names></name><name name-style="western"><surname>Byron</surname><given-names>Baron</given-names></name><article-title>The role of TNF-&#945; in rheumatoid arthritis: a focus on regulatory T cells</article-title><source>J Clin Transl Res</source><year>2016</year><volume>2</volume><fpage>84</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">30873466</pub-id><pub-id pub-id-type="pmcid">PMC6410649</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_052"><label>[52]</label><element-citation publication-type="journal"><name name-style="western"><surname>Wong</surname><given-names>M</given-names></name><name name-style="western"><surname>La</surname><given-names>Cava A</given-names></name><article-title>Lupus, the current therapeutic approaches</article-title><source>Drugs Today (Barc)</source><year>2011</year><volume>47</volume><fpage>289</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">21573252</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1358/dot.2011.47.4.1583186</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_053"><label>[53]</label><element-citation publication-type="journal"><name name-style="western"><surname>La</surname><given-names>Cava A</given-names></name><name name-style="western"><surname>Ebling</surname><given-names>FM</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>BH</given-names></name><article-title>Ig-reactive CD4+CD25+ T cells from tolerized (New Zealand Black x New Zealand White) F1 mice suppress in vitro production of antibodies to DNA</article-title><source>J Immunol</source><year>2004</year><volume>173</volume><fpage>3542</fpage><lpage>3548</lpage><pub-id pub-id-type="pmid">15322219</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.173.5.3542</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_054"><label>[54]</label><element-citation publication-type="journal"><name name-style="western"><surname>Iikuni</surname><given-names>N</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>BH</given-names></name><name name-style="western"><surname>La</surname><given-names>Cava A</given-names></name><article-title>Potential for anti-DNA immunoglobulin peptide therapy in systemic lupus erythematosus</article-title><source>Expert Opin Biol Ther</source><year>2009</year><volume>9</volume><fpage>201</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">19236250</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/14712590802681636</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_055"><label>[55]</label><element-citation publication-type="journal"><name name-style="western"><surname>Iikuni</surname><given-names>N</given-names></name><name name-style="western"><surname>Louren&#231;o</surname><given-names>EV</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>BH</given-names></name><comment>et al</comment><article-title>Cutting edge: Regulatory T cells directly suppress B cells in systemic lupus erythematosus</article-title><source>J Immunol</source><year>2009</year><volume>183</volume><fpage>1518</fpage><lpage>1522</lpage><pub-id pub-id-type="pmid">19570829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.0901163</pub-id><pub-id pub-id-type="pmcid">PMC2730469</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_056"><label>[56]</label><element-citation publication-type="journal"><name name-style="western"><surname>Singh</surname><given-names>RR</given-names></name><name name-style="western"><surname>Ebling</surname><given-names>FM</given-names></name><name name-style="western"><surname>Sercarz</surname><given-names>EE</given-names></name><comment>et al</comment><article-title>Immune tolerance to autoantibody-derived peptides delays development of autoimmunity in murine lupus</article-title><source>J Clin Invest</source><year>1995</year><volume>96</volume><fpage>2990</fpage><lpage>2996</lpage><pub-id pub-id-type="pmid">8675671</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI118371</pub-id><pub-id pub-id-type="pmcid">PMC186011</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_057"><label>[57]</label><element-citation publication-type="journal"><name name-style="western"><surname>Skaggs</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Singh</surname><given-names>RP</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>BH</given-names></name><article-title>Induction of immune tolerance by activation of CD8+ T suppressor/regulatory cells in lupus-prone mice</article-title><source>Hum Immunol</source><year>2008</year><volume>69</volume><fpage>790</fpage><lpage>796</lpage><pub-id pub-id-type="pmid">18817829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.humimm.2008.08.284</pub-id><pub-id pub-id-type="pmcid">PMC2621070</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_058"><label>[58]</label><element-citation publication-type="journal"><name name-style="western"><surname>Hahn</surname><given-names>BH</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>M</given-names></name><name name-style="western"><surname>Le</surname><given-names>E</given-names></name><comment>et al</comment><article-title>Anti-DNA Ig peptides promote Treg cell activity in systemic lupus erythematosus patients</article-title><source>Arthritis Rheum</source><year>2008</year><volume>58</volume><fpage>2488</fpage><lpage>2497</lpage><pub-id pub-id-type="pmid">18668553</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/art.23609</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_059"><label>[59]</label><element-citation publication-type="journal"><name name-style="western"><surname>Sharabi</surname><given-names>A</given-names></name><name name-style="western"><surname>Zinger</surname><given-names>H</given-names></name><name name-style="western"><surname>Zborowsky</surname><given-names>M</given-names></name><comment>et al</comment><article-title>A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4+CD25+ cells and TGF-beta</article-title><source>Proc Natl Acad Sci U S A</source><year>2006</year><volume>103</volume><fpage>8810</fpage><lpage>8815</lpage><pub-id pub-id-type="pmid">16735466</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0603201103</pub-id><pub-id pub-id-type="pmcid">PMC1482660</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_060"><label>[60]</label><element-citation publication-type="journal"><name name-style="western"><surname>Sthoeger</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zinger</surname><given-names>H</given-names></name><name name-style="western"><surname>Sharabi</surname><given-names>A</given-names></name><comment>et al</comment><article-title>The tolerogenic peptide, hCDR1, down-regulates the expression of interferon-&#945; in murine and human systemic lupus erythematosus</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e60394</fpage><pub-id pub-id-type="pmid">23555966</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0060394</pub-id><pub-id pub-id-type="pmcid">PMC3610660</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_061"><label>[61]</label><element-citation publication-type="journal"><name name-style="western"><surname>Waisman</surname><given-names>A</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Israeli</surname><given-names>E</given-names></name><comment>et al</comment><article-title>Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of a pathogenic anti-DNA monoclonal antibody</article-title><source>Proc Natl Acad Sci U S A</source><year>1997</year><volume>94</volume><fpage>4620</fpage><lpage>4625</lpage><pub-id pub-id-type="pmid">9114040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.94.9.4620</pub-id><pub-id pub-id-type="pmcid">PMC20773</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_062"><label>[62]</label><element-citation publication-type="journal"><name name-style="western"><surname>Crisp&#237;n</surname><given-names>JC</given-names></name><name name-style="western"><surname>Kyttaris</surname><given-names>VC</given-names></name><name name-style="western"><surname>Terhorst</surname><given-names>C</given-names></name><comment>et al</comment><article-title>T cells as therapeutic targets in SLE</article-title><source>Nat Rev Rheumatol</source><year>2010</year><volume>6</volume><fpage>317</fpage><lpage>325</lpage><pub-id pub-id-type="pmid">20458333</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrrheum.2010.60</pub-id><pub-id pub-id-type="pmcid">PMC2924434</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_063"><label>[63]</label><element-citation publication-type="journal"><name name-style="western"><surname>Dinesh</surname><given-names>RK</given-names></name><name name-style="western"><surname>Skaggs</surname><given-names>BJ</given-names></name><name name-style="western"><surname>La</surname><given-names>Cava A</given-names></name><comment>et al</comment><article-title>CD8+ Tregs in lupus, autoimmunity, and beyond</article-title><source>Autoimmun Rev</source><year>2010</year><volume>9</volume><fpage>560</fpage><lpage>568</lpage><pub-id pub-id-type="pmid">20385256</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.autrev.2010.03.006</pub-id><pub-id pub-id-type="pmcid">PMC2879466</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_064"><label>[64]</label><element-citation publication-type="journal"><name name-style="western"><surname>Horwitz</surname><given-names>DA</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>SG</given-names></name><name name-style="western"><surname>Gray</surname><given-names>JD</given-names></name><comment>et al</comment><article-title>Regulatory T cells generated ex vivo as an approach for the therapy of autoimmune disease</article-title><source>Semin Immunol</source><year>2004</year><volume>16</volume><fpage>135</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">15036237</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.smim.2003.12.009</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_065"><label>[65]</label><element-citation publication-type="journal"><name name-style="western"><surname>Rapoport</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Sharabi</surname><given-names>A</given-names></name><name name-style="western"><surname>Aharoni</surname><given-names>D</given-names></name><comment>et al</comment><article-title>Amelioration of SLE-like manifestations in (NZBxNZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a down-regulation of apoptosis and of the pro-apoptotic factor JNK kinase</article-title><source>Clin Immunol</source><year>2005</year><volume>117</volume><fpage>262</fpage><lpage>270</lpage><pub-id pub-id-type="pmid">16257268</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clim.2005.09.003</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_066"><label>[66]</label><element-citation publication-type="journal"><name name-style="western"><surname>Sthoeger</surname><given-names>Z</given-names></name><name name-style="western"><surname>Sharabi</surname><given-names>A</given-names></name><name name-style="western"><surname>Mozes</surname><given-names>E</given-names></name><article-title>Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus</article-title><source>J Autoimmun</source><year>2014</year><volume>54</volume><fpage>60</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">24958634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaut.2014.06.002</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_067"><label>[67]</label><element-citation publication-type="journal"><name name-style="western"><surname>Parameswaran</surname><given-names>R</given-names></name><name name-style="western"><surname>Ben</surname><given-names>David H</given-names></name><name name-style="western"><surname>Sharabi</surname><given-names>A</given-names></name><comment>et al</comment><article-title>B-cell activating factor (BAFF) plays a role in the mechanism of action of a tolerogenic peptide that ameliorates lupus</article-title><source>Clin Immunol</source><year>2009</year><volume>131</volume><fpage>223</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">19188092</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clim.2008.12.009</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_068"><label>[68]</label><element-citation publication-type="journal"><name name-style="western"><surname>Lapter</surname><given-names>S</given-names></name><name name-style="western"><surname>Marom</surname><given-names>A</given-names></name><name name-style="western"><surname>Meshorer</surname><given-names>A</given-names></name><comment>et al</comment><article-title>Amelioration of brain pathology and behavioral dysfunction in mice with lupus following treatment with a tolerogenic peptide</article-title><source>Arthritis Rheum</source><year>2009</year><volume>60</volume><fpage>3744</fpage><lpage>3754</lpage><pub-id pub-id-type="pmid">19950283</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/art.25013</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_069"><label>[69]</label><element-citation publication-type="journal"><name name-style="western"><surname>Urowitz</surname><given-names>MB</given-names></name><name name-style="western"><surname>Isenberg</surname><given-names>DA</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>DJ</given-names></name><article-title>Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study</article-title><source>Lupus Sci Med</source><year>2015</year><volume>2</volume><fpage>e000104</fpage><pub-id pub-id-type="pmid">26301100</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/lupus-2015-000104</pub-id><pub-id pub-id-type="pmcid">PMC4538379</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_070"><label>[70]</label><element-citation publication-type="journal"><name name-style="western"><surname>Kang</surname><given-names>HK</given-names></name><name name-style="western"><surname>Michaels</surname><given-names>MA</given-names></name><name name-style="western"><surname>Berner</surname><given-names>BR</given-names></name><comment>et al</comment><article-title>Very low-dose tolerance with nucleosomal peptides controls lupus and induces potent regulatory T cell subsets</article-title><source>J Immunol</source><year>2005</year><volume>174</volume><fpage>3247</fpage><lpage>3255</lpage><pub-id pub-id-type="pmid">15749855</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.174.6.3247</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_071"><label>[71]</label><element-citation publication-type="journal"><name name-style="western"><surname>Kang</surname><given-names>JY</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JO</given-names></name><article-title>Structural biology of the Toll-like receptor family</article-title><source>Annu Rev Biochem</source><year>2011</year><volume>80</volume><fpage>917</fpage><lpage>941</lpage><pub-id pub-id-type="pmid">21548780</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-biochem-052909-141507</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_072"><label>[72]</label><element-citation publication-type="journal"><name name-style="western"><surname>Kang</surname><given-names>SM</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Bluestone</surname><given-names>JA</given-names></name><article-title>CD4+CD25+ regulatory T cells in transplantation: progress, challenges and prospects</article-title><source>Am J Transplant</source><year>2007</year><volume>7</volume><fpage>1457</fpage><lpage>1463</lpage><pub-id pub-id-type="pmid">17511675</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1600-6143.2007.01829.x</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_073"><label>[73]</label><element-citation publication-type="journal"><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Bertucci</surname><given-names>AM</given-names></name><name name-style="western"><surname>Ramsey-Goldman</surname><given-names>R</given-names></name><comment>et al</comment><article-title>Regulatory T cell (Treg) subsets return in patients with refractory lupus following stem cell transplantation, and TGF-beta-producing CD8+ Treg cells are associated with immunological remission of lupus</article-title><source>J Immunol</source><year>2009</year><volume>183</volume><fpage>6346</fpage><lpage>6358</lpage><pub-id pub-id-type="pmid">19841178</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.0901773</pub-id><pub-id pub-id-type="pmcid">PMC2784684</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_074"><label>[74]</label><element-citation publication-type="journal"><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Bertucci</surname><given-names>AM</given-names></name><name name-style="western"><surname>Ramsey-Goldman</surname><given-names>R</given-names></name><comment>et al</comment><article-title>Major pathogenic steps in human lupus can be effectively suppressed by nucleosomal histone peptide epitope-induced regulatory immunity</article-title><source>Clin Immunol</source><year>2013</year><volume>149</volume><fpage>365</fpage><lpage>378</lpage><pub-id pub-id-type="pmid">24211843</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clim.2013.08.008</pub-id><pub-id pub-id-type="pmcid">PMC3849335</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_075"><label>[75]</label><element-citation publication-type="journal"><name name-style="western"><surname>Shapira</surname><given-names>E</given-names></name><name name-style="western"><surname>Proscura</surname><given-names>E</given-names></name><name name-style="western"><surname>Brodsky</surname><given-names>B</given-names></name><comment>et al</comment><article-title>Novel peptides as potential treatment of systemic lupus erythematosus</article-title><source>Lupus</source><year>2011</year><volume>20</volume><fpage>463</fpage><lpage>472</lpage><pub-id pub-id-type="pmid">21335402</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0961203310389484</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_076"><label>[76]</label><element-citation publication-type="journal"><name name-style="western"><surname>Wu</surname><given-names>HY</given-names></name><name name-style="western"><surname>Staines</surname><given-names>NA</given-names></name><article-title>A deficiency of CD4+CD25+ T cells permits the development of spontaneous lupus-like disease in mice, and can be reversed by induction of mucosal tolerance to histone peptide autoantigen</article-title><source>Lupus</source><year>2004</year><volume>13</volume><fpage>192</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">15119549</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1191/0961203303lu1002oa</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_077"><label>[77]</label><element-citation publication-type="journal"><name name-style="western"><surname>Wu</surname><given-names>HY</given-names></name><name name-style="western"><surname>Ward</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Staines</surname><given-names>NA</given-names></name><article-title>Histone peptide-induced nasal tolerance: suppression of murine lupus</article-title><source>J Immunol</source><year>2002</year><volume>169</volume><fpage>1126</fpage><lpage>1134</lpage><pub-id pub-id-type="pmid">12097422</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.169.2.1126</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_078"><label>[78]</label><element-citation publication-type="journal"><name name-style="western"><surname>Monneaux</surname><given-names>F</given-names></name><name name-style="western"><surname>Lozano</surname><given-names>JM</given-names></name><name name-style="western"><surname>Patarroyo</surname><given-names>ME</given-names></name><comment>et al</comment><article-title>T cell recognition and therapeutic effect of a phosphorylated synthetic peptide of the 70K snRNP protein administered in MR/lpr mice</article-title><source>Eur J Immunol</source><year>2003</year><volume>33</volume><fpage>287</fpage><lpage>296</lpage><pub-id pub-id-type="pmid">12548559</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/immu.200310002</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_079"><label>[79]</label><element-citation publication-type="journal"><name name-style="western"><surname>Page</surname><given-names>N</given-names></name><name name-style="western"><surname>Gros</surname><given-names>F</given-names></name><name name-style="western"><surname>Schall</surname><given-names>N</given-names></name><comment>et al</comment><article-title>A therapeutic peptide in lupus alters autophagic processes and stability of MHCII molecules in MRL/lpr B cells</article-title><source>Autophagy</source><year>2011</year><volume>7</volume><fpage>539</fpage><lpage>540</lpage><pub-id pub-id-type="pmid">21282971</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/auto.7.5.14845</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_080"><label>[80]</label><element-citation publication-type="journal"><name name-style="western"><surname>Wilhelm</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name><name name-style="western"><surname>Schall</surname><given-names>N</given-names></name><comment>et al</comment><article-title>Lupus Regulator Peptide P140 Represses B Cell Differentiation by Reducing HLA Class II Molecule Overexpression</article-title><source>Arthritis Rheumatol</source><year>2018</year><volume>70</volume><fpage>1077</fpage><lpage>1088</lpage><pub-id pub-id-type="pmid">29499102</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/art.40470</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_081"><label>[81]</label><element-citation publication-type="journal"><name name-style="western"><surname>Muller</surname><given-names>S</given-names></name><name name-style="western"><surname>Monneaux</surname><given-names>F</given-names></name><name name-style="western"><surname>Schall</surname><given-names>N</given-names></name><comment>et al</comment><article-title>Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial</article-title><source>Arthritis Rheum</source><year>2008</year><volume>58</volume><fpage>3873</fpage><lpage>3883</lpage><pub-id pub-id-type="pmid">19035498</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/art.24027</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_082"><label>[82]</label><element-citation publication-type="journal"><name name-style="western"><surname>Zimmer</surname><given-names>R</given-names></name><name name-style="western"><surname>Scherbarth</surname><given-names>HR</given-names></name><name name-style="western"><surname>Rillo</surname><given-names>OL</given-names></name><comment>et al</comment><article-title>Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial</article-title><source>Ann Rheum Dis</source><year>2013</year><volume>72</volume><fpage>1830</fpage><lpage>1835</lpage><pub-id pub-id-type="pmid">23172751</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/annrheumdis-2012-202460</pub-id><pub-id pub-id-type="pmcid">PMC3812851</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_083"><label>[83]</label><element-citation publication-type="journal"><name name-style="western"><surname>Bosch</surname><given-names>X</given-names></name><name name-style="western"><surname>Ramos-Casals</surname><given-names>M</given-names></name><name name-style="western"><surname>Khamashta</surname><given-names>MA</given-names></name><article-title>The DWEYS peptide in systemic lupus erythematosus</article-title><source>Trends Mol Med</source><year>2012</year><volume>18</volume><fpage>215</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">22365619</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmed.2012.01.008</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_084"><label>[84]</label><element-citation publication-type="journal"><name name-style="western"><surname>DeGiorgio</surname><given-names>LA</given-names></name><name name-style="western"><surname>Konstantinov</surname><given-names>KN</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SC</given-names></name><comment>et al</comment><article-title>A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus</article-title><source>Nat Med</source><year>2001</year><volume>7</volume><fpage>1189</fpage><lpage>1193</lpage><pub-id pub-id-type="pmid">11689882</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm1101-1189</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_085"><label>[85]</label><element-citation publication-type="journal"><name name-style="western"><surname>Gaynor</surname><given-names>B</given-names></name><name name-style="western"><surname>Putterman</surname><given-names>C</given-names></name><name name-style="western"><surname>Valadon</surname><given-names>P</given-names></name><comment>et al</comment><article-title>Peptide inhibition of glomerular deposition of an anti-DNA antibody</article-title><source>Proc Natl Acad Sci U S A</source><year>1997</year><volume>94</volume><fpage>1955</fpage><lpage>1960</lpage><pub-id pub-id-type="pmid">9050886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.94.5.1955</pub-id><pub-id pub-id-type="pmcid">PMC20024</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_086"><label>[86]</label><element-citation publication-type="journal"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>S</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Y</given-names></name><comment>et al</comment><article-title>The Therapeutic Strategies for SLE by Targeting Anti-dsDNA Antibodies</article-title><source>Clin Rev Allergy Immunol</source><year>2022</year><volume>63</volume><fpage>152</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">34542806</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12016-021-08898-7</pub-id><pub-id pub-id-type="pmcid">PMC9464114</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_087"><label>[87]</label><element-citation publication-type="journal"><name name-style="western"><surname>Shefner</surname><given-names>R</given-names></name><name name-style="western"><surname>Kleiner</surname><given-names>G</given-names></name><name name-style="western"><surname>Turken</surname><given-names>A</given-names></name><comment>et al</comment><article-title>A novel class of anti-DNA antibodies identified in BALB/c mice</article-title><source>J Exp Med</source><year>1991</year><volume>173</volume><fpage>287</fpage><lpage>296</lpage><pub-id pub-id-type="pmid">1988536</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.173.2.287</pub-id><pub-id pub-id-type="pmcid">PMC2118791</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_088"><label>[88]</label><element-citation publication-type="journal"><name name-style="western"><surname>Diamond</surname><given-names>B</given-names></name><name name-style="western"><surname>Bloom</surname><given-names>O</given-names></name><name name-style="western"><surname>Al</surname><given-names>Abed Y</given-names></name><comment>et al</comment><article-title>Moving towards a cure: blocking pathogenic antibodies in systemic lupus erythematosus</article-title><source>J Intern Med</source><year>2011</year><volume>269</volume><fpage>36</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">21158976</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2796.2010.02318.x</pub-id><pub-id pub-id-type="pmcid">PMC3069637</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_089"><label>[89]</label><element-citation publication-type="journal"><name name-style="western"><surname>Sharma</surname><given-names>A</given-names></name><name name-style="western"><surname>Isenberg</surname><given-names>D</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>B</given-names></name><article-title>Studies of human polyclonal and monoclonal antibodies binding to lupus autoantigens and cross-reactive antigens</article-title><source>Rheumatology (Oxford)</source><year>2003</year><volume>42</volume><fpage>453</fpage><lpage>463</lpage><pub-id pub-id-type="pmid">12626796</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/rheumatology/keg161</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_090"><label>[90]</label><element-citation publication-type="journal"><name name-style="western"><surname>Voynova</surname><given-names>E</given-names></name><name name-style="western"><surname>Tchorbanov</surname><given-names>A</given-names></name><name name-style="western"><surname>Prechl</surname><given-names>J</given-names></name><comment>et al</comment><article-title>An antibody-based construct carrying DNA-mimotope and targeting CR1(CD35) selectively suppresses human autoreactive B-lymphocytes</article-title><source>Immunol Lett</source><year>2008</year><volume>116</volume><fpage>168</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">18262286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.imlet.2007.12.016</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_091"><label>[91]</label><element-citation publication-type="journal"><name name-style="western"><surname>Bloom</surname><given-names>O</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>KF</given-names></name><name name-style="western"><surname>He</surname><given-names>M</given-names></name><comment>et al</comment><article-title>Generation of a unique small molecule peptidomimetic that neutralizes lupus autoantibody activity</article-title><source>Proc Natl Acad Sci U S A</source><year>2011</year><volume>108</volume><fpage>10255</fpage><lpage>10259</lpage><pub-id pub-id-type="pmid">21646518</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1103555108</pub-id><pub-id pub-id-type="pmcid">PMC3121823</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_092"><label>[92]</label><element-citation publication-type="journal"><name name-style="western"><surname>He</surname><given-names>M</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>KF</given-names></name><name name-style="western"><surname>VanPatten</surname><given-names>S</given-names></name><comment>et al</comment><article-title>A structural investigation of FISLE-412, a peptidomimetic compound derived from saquinavir that targets lupus autoantibodies</article-title><source>Bioorg Med Chem Lett</source><year>2017</year><volume>27</volume><fpage>4725</fpage><lpage>4729</lpage><pub-id pub-id-type="pmid">28927788</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bmcl.2017.08.070</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_093"><label>[93]</label><element-citation publication-type="journal"><name name-style="western"><surname>VanPatten</surname><given-names>S</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S</given-names></name><name name-style="western"><surname>He</surname><given-names>M</given-names></name><comment>et al</comment><article-title>Amending HIV Drugs: A Novel Small-Molecule Approach To Target Lupus Anti-DNA Antibodies</article-title><source>J Med Chem</source><year>2016</year><volume>59</volume><fpage>8859</fpage><lpage>8867</lpage><pub-id pub-id-type="pmid">27603688</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.6b00694</pub-id><pub-id pub-id-type="pmcid">PMC5592695</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_094"><label>[94]</label><element-citation publication-type="journal"><name name-style="western"><surname>Altiti</surname><given-names>AS</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>KF</given-names></name><name name-style="western"><surname>He</surname><given-names>M</given-names></name><comment>et al</comment><article-title>&#946;-Hydroxy-tetrahydroquinolines from Quinolines Using Chloroborane: Synthesis of the Peptidomimetic FISLE-412</article-title><source>Chemistry</source><year>2017</year><volume>23</volume><fpage>10738</fpage><lpage>10743</lpage><pub-id pub-id-type="pmid">28639294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/chem.201701944</pub-id><pub-id pub-id-type="pmcid">PMC6003427</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_095"><label>[95]</label><element-citation publication-type="journal"><name name-style="western"><surname>Xia</surname><given-names>Y</given-names></name><name name-style="western"><surname>Eryilmaz</surname><given-names>E</given-names></name><name name-style="western"><surname>Der</surname><given-names>E</given-names></name><comment>et al</comment><article-title>A peptide mimic blocks the cross-reaction of anti-DNA antibodies with glomerular antigens</article-title><source>Clin Exp Immunol</source><year>2016</year><volume>183</volume><fpage>369</fpage><lpage>379</lpage><pub-id pub-id-type="pmid">26482679</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cei.12734</pub-id><pub-id pub-id-type="pmcid">PMC4750606</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_096"><label>[96]</label><element-citation publication-type="journal"><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Lu</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhai</surname><given-names>S</given-names></name><comment>et al</comment><article-title>ALW peptide ameliorates lupus nephritis in MRL/lpr mice</article-title><source>Arthritis Res Ther</source><year>2019</year><volume>21</volume><fpage>261</fpage><pub-id pub-id-type="pmid">31791413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13075-019-2038-0</pub-id><pub-id pub-id-type="pmcid">PMC6889545</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_097"><label>[97]</label><element-citation publication-type="journal"><name name-style="western"><surname>Sibylle</surname><given-names>Hoeppe</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>D Schreiber</given-names></name><name name-style="western"><surname>Hannes</surname><given-names>Planatscher</given-names></name><comment>et al</comment><article-title>Targeting peptide termini, a novel immunoaffinity approach to reduce complexity in mass spectrometric protein identification</article-title><source>Mol Cell Proteomics</source><year>2011</year><volume>10</volume><fpage>M110</fpage><comment>DOI</comment><pub-id pub-id-type="doi">10.1074/mcpM110.002857]</pub-id><pub-id pub-id-type="pmcid">PMC3033676</pub-id><pub-id pub-id-type="pmid">20962300</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_098"><label>[98]</label><element-citation publication-type="journal"><name name-style="western"><surname>Horowitz</surname><given-names>DM</given-names></name><name name-style="western"><surname>Furie</surname><given-names>RA</given-names></name><article-title>Abetimus sodium: a medication for the prevention of lupus nephritis flares</article-title><source>Expert Opin Pharmacother</source><year>2009</year><volume>10</volume><fpage>1501</fpage><lpage>1507</lpage><pub-id pub-id-type="pmid">19505217</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/14656560902946419</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_099"><label>[99]</label><element-citation publication-type="journal"><name name-style="western"><surname>Wallace</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Tumlin</surname><given-names>JA</given-names></name><article-title>LJP 394 (abetimus sodium, Riquent) in the management of systemic lupus erythematosus</article-title><source>Lupus</source><year>2004</year><volume>13</volume><fpage>323</fpage><lpage>327</lpage><pub-id pub-id-type="pmid">15230286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1191/0961203304lu1020oa</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_100"><label>[100]</label><element-citation publication-type="journal"><name name-style="western"><surname>Lorenz</surname><given-names>HM</given-names></name><article-title>Abetimus (La Jolla pharmaceuticals)</article-title><source>Curr Opin Investig Drugs</source><year>2002</year><volume>3</volume><fpage>234</fpage><lpage>239</lpage><pub-id pub-id-type="pmid">12020052</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_101"><label>[101]</label><element-citation publication-type="journal"><name name-style="western"><surname>Mosca</surname><given-names>M</given-names></name><name name-style="western"><surname>Baldini</surname><given-names>C</given-names></name><name name-style="western"><surname>Bombardieri</surname><given-names>S</given-names></name><article-title>LJP-394 (abetimus sodium) in the treatment of systemic lupus erythematosus</article-title><source>Expert Opin Pharmacother</source><year>2007</year><volume>8</volume><fpage>873</fpage><lpage>879</lpage><pub-id pub-id-type="pmid">17425481</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/14656566.8.6.873</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_102"><label>[102]</label><element-citation publication-type="journal"><name name-style="western"><surname>Richard</surname><given-names>Furie</given-names></name><article-title>Abetimus sodium (riquent) for the prevention of nephritic flares in patients with systemic lupus erythematosus</article-title><source>Rheum Dis Clin North Am</source><year>2006</year><volume>32</volume><fpage>149</fpage><lpage>156</lpage><comment>DOI</comment><pub-id pub-id-type="doi">10.1016/j.rdc.2005.11.001]</pub-id><pub-id pub-id-type="pmid">16504827</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_103"><label>[103]</label><element-citation publication-type="journal"><name name-style="western"><surname>Cardiel</surname><given-names>MH</given-names></name><name name-style="western"><surname>Tumlin</surname><given-names>JA</given-names></name><name name-style="western"><surname>Furie</surname><given-names>RA</given-names></name><comment>et al</comment><article-title>Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial</article-title><source>Arthritis Rheum</source><year>2008</year><volume>58</volume><fpage>2470</fpage><lpage>2480</lpage><pub-id pub-id-type="pmid">18668592</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/art.23673</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_104"><label>[104]</label><element-citation publication-type="journal"><name name-style="western"><surname>Gharagozloo</surname><given-names>M</given-names></name><name name-style="western"><surname>Majewski</surname><given-names>S</given-names></name><name name-style="western"><surname>Foldvari</surname><given-names>M</given-names></name><article-title>Therapeutic applications of nanomedicine in autoimmune diseases: from immunosuppression to tolerance induction</article-title><source>Nanomedicine (Lond)</source><year>2015</year><volume>11</volume><fpage>1003</fpage><lpage>1018</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nano.2014.12.003</pub-id><pub-id pub-id-type="pmid">25596076</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_105"><label>[105]</label><element-citation publication-type="journal"><name name-style="western"><surname>Horwitz</surname><given-names>DA</given-names></name><name name-style="western"><surname>Bickerton</surname><given-names>S</given-names></name><name name-style="western"><surname>La</surname><given-names>Cava A</given-names></name><article-title>Strategies to Use Nanoparticles to Generate CD4 and CD8 Regulatory T Cells for the Treatment of SLE and Other Autoimmune Diseases</article-title><source>Front Immunol</source><year>2021</year><volume>12</volume><fpage>681062</fpage><pub-id pub-id-type="pmid">34211471</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2021.681062</pub-id><pub-id pub-id-type="pmcid">PMC8239238</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_106"><label>[106]</label><element-citation publication-type="journal"><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Santamaria</surname><given-names>P</given-names></name><article-title>Evolution of nanomedicines for the treatment of autoimmune disease: From vehicles for drug delivery to inducers of bystander immunoregulation</article-title><source>Adv Drug Deliv Rev</source><year>2021</year><volume>176</volume><fpage>113898</fpage><pub-id pub-id-type="pmid">34314782</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2021.113898</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_107"><label>[107]</label><element-citation publication-type="journal"><name name-style="western"><surname>Ferretti</surname><given-names>C</given-names></name><name name-style="western"><surname>Horwitz</surname><given-names>DA</given-names></name><name name-style="western"><surname>Bickerton</surname><given-names>S</given-names></name><comment>et al</comment><article-title>Nanoparticle-mediated Delivery of IL-2 To T Follicular Helper Cells Protects BDF1 Mice from Lupus-like Disease</article-title><source>Rheumatol Immunol Res</source><year>2021</year><volume>2</volume><fpage>185</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">36465067</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2478/rir-2021-0024</pub-id><pub-id pub-id-type="pmcid">PMC9524795</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_108"><label>[108]</label><element-citation publication-type="journal"><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Yang</surname><given-names>YG</given-names></name><name name-style="western"><surname>Sun</surname><given-names>T</given-names></name><article-title>Nanoparticle-Based Drug Delivery Systems for Induction of Tolerance and Treatment of Autoimmune Diseases</article-title><source>Front Bioeng Biotechnol</source><year>2022</year><volume>10</volume><fpage>889291</fpage><pub-id pub-id-type="pmid">35464732</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fbioe.2022.889291</pub-id><pub-id pub-id-type="pmcid">PMC9019755</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_109"><label>[109]</label><element-citation publication-type="journal"><name name-style="western"><surname>Schall</surname><given-names>N</given-names></name><name name-style="western"><surname>Talamini</surname><given-names>L</given-names></name><name name-style="western"><surname>Wilhelm</surname><given-names>M</given-names></name><comment>et al</comment><article-title>P140 Peptide Leads to Clearance of Autoreactive Lymphocytes and Normalizes Immune Response in Lupus-Prone Mice</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>904669</fpage><pub-id pub-id-type="pmid">35720371</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.904669</pub-id><pub-id pub-id-type="pmcid">PMC9199391</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_110"><label>[110]</label><element-citation publication-type="journal"><name name-style="western"><surname>Horwitz</surname><given-names>DA</given-names></name><name name-style="western"><surname>Bickerton</surname><given-names>S</given-names></name><name name-style="western"><surname>Koss</surname><given-names>M</given-names></name><comment>et al</comment><article-title>Suppression of Murine Lupus by CD4+ and CD8+ Treg Cells Induced by T Cell-Targeted Nanoparticles Loaded With Interleukin-2 and Transforming Growth Factor &#946;</article-title><source>Arthritis Rheumatol</source><year>2019</year><volume>71</volume><fpage>632</fpage><lpage>640</lpage><pub-id pub-id-type="pmid">30407752</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/art.40773</pub-id><pub-id pub-id-type="pmcid">PMC6438734</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_111"><label>[111]</label><element-citation publication-type="journal"><name name-style="western"><surname>Otomo</surname><given-names>K</given-names></name><name name-style="western"><surname>Koga</surname><given-names>T</given-names></name><name name-style="western"><surname>Mizui</surname><given-names>M</given-names></name><comment>et al</comment><article-title>Cutting Edge: Nanogel-Based Delivery of an Inhibitor of CaMK4 to CD4+ T Cells Suppresses Experimental Autoimmune Encephalomyelitis and Lupus-like Disease in Mice</article-title><source>J Immunol</source><year>2015</year><volume>195</volume><fpage>5533</fpage><lpage>5537</lpage><pub-id pub-id-type="pmid">26561550</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1501603</pub-id><pub-id pub-id-type="pmcid">PMC4670795</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_112"><label>[112]</label><element-citation publication-type="journal"><name name-style="western"><surname>Maeda</surname><given-names>K</given-names></name><name name-style="western"><surname>Otomo</surname><given-names>K</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>N</given-names></name><comment>et al</comment><article-title>CaMK4 compromises podocyte function in autoimmune and nonautoimmune kidney disease</article-title><source>J Clin Invest</source><year>2018</year><volume>128</volume><fpage>3445</fpage><lpage>3459</lpage><pub-id pub-id-type="pmid">29985166</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI99507</pub-id><pub-id pub-id-type="pmcid">PMC6063476</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_113"><label>[113]</label><element-citation publication-type="journal"><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Fu</surname><given-names>H</given-names></name><comment>et al</comment><article-title>MicroRNA-125a-Loaded Polymeric Nanoparticles Alleviate Systemic Lupus Erythematosus by Restoring Effector/Regulatory T Cells Balance</article-title><source>ACS Nano</source><year>2020</year><volume>14</volume><fpage>4414</fpage><lpage>4429</lpage><pub-id pub-id-type="pmid">32203665</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.9b09998</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_114"><label>[114]</label><element-citation publication-type="journal"><name name-style="western"><surname>Heidegger</surname><given-names>S</given-names></name><name name-style="western"><surname>G&#246;ssl</surname><given-names>D</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>A</given-names></name><comment>et al</comment><article-title>Immune response to functionalized mesoporous silica nanoparticles for targeted drug delivery</article-title><source>Nanoscale</source><year>2016</year><volume>8</volume><fpage>938</fpage><lpage>948</lpage><pub-id pub-id-type="pmid">26659601</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c5nr06122a</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_115"><label>[115]</label><element-citation publication-type="journal"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Han</surname><given-names>N</given-names></name><comment>et al</comment><article-title>Mesoporous silica nanoparticles in drug delivery and biomedical applications</article-title><source>Nanomedicine (Lond)</source><year>2015</year><volume>11</volume><fpage>313</fpage><lpage>327</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nano.2014.09.014</pub-id><pub-id pub-id-type="pmid">25461284</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_116"><label>[116]</label><element-citation publication-type="journal"><name name-style="western"><surname>Xu</surname><given-names>C</given-names></name><name name-style="western"><surname>Lei</surname><given-names>C</given-names></name><name name-style="western"><surname>Yu</surname><given-names>C</given-names></name><article-title>Mesoporous Silica Nanoparticles for Protein Protection and Delivery</article-title><source>Front Chem</source><year>2019</year><volume>7</volume><fpage>290</fpage><pub-id pub-id-type="pmid">31119124</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fchem.2019.00290</pub-id><pub-id pub-id-type="pmcid">PMC6504683</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_117"><label>[117]</label><element-citation publication-type="journal"><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Quan</surname><given-names>G</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q</given-names></name><comment>et al</comment><article-title>Mesoporous silica nanoparticles for drug and gene delivery</article-title><source>Acta Pharm Sin B</source><year>2018</year><volume>8</volume><fpage>165</fpage><lpage>177</lpage><pub-id pub-id-type="pmid">29719777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2018.01.007</pub-id><pub-id pub-id-type="pmcid">PMC5926503</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_118"><label>[118]</label><element-citation publication-type="journal"><name name-style="western"><surname>Look</surname><given-names>M</given-names></name><name name-style="western"><surname>Saltzman</surname><given-names>WM</given-names></name><name name-style="western"><surname>Craft</surname><given-names>J</given-names></name><comment>et al</comment><article-title>The nanomaterial-dependent modulation of dendritic cells and its potential influence on therapeutic immunosuppression in lupus</article-title><source>Biomaterials</source><year>2014</year><volume>35</volume><fpage>1089</fpage><lpage>1095</lpage><pub-id pub-id-type="pmid">24183697</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2013.10.046</pub-id><pub-id pub-id-type="pmcid">PMC4164020</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_119"><label>[119]</label><element-citation publication-type="journal"><name name-style="western"><surname>Look</surname><given-names>M</given-names></name><name name-style="western"><surname>Stern</surname><given-names>E</given-names></name><name name-style="western"><surname>Wang</surname><given-names>QA</given-names></name><comment>et al</comment><article-title>Nanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus in mice</article-title><source>J Clin Invest</source><year>2013</year><volume>123</volume><fpage>1741</fpage><lpage>1749</lpage><pub-id pub-id-type="pmid">23454752</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI65907</pub-id><pub-id pub-id-type="pmcid">PMC3613921</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_120"><label>[120]</label><element-citation publication-type="journal"><name name-style="western"><surname>Song</surname><given-names>X</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><comment>et al</comment><article-title>Rapamycin alleviates renal damage in mice with systemic lupus erythematosus through improving immune response and function</article-title><source>Biomed Pharmacother</source><year>2021</year><volume>137</volume><fpage>111289</fpage><pub-id pub-id-type="pmid">33581650</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2021.111289</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_121"><label>[121]</label><element-citation publication-type="journal"><name name-style="western"><surname>Li-fu</surname><given-names>Miao</given-names></name><name name-style="western"><surname>Jing</surname><given-names>Yang</given-names></name><name name-style="western"><surname>Chao-lian</surname><given-names>Huang</given-names></name><comment>et al</comment><article-title>[Rapamycinloaded poly (lactic-co-glycolic) acid nanoparticles for intraarterial local drug delivery: preparation, characterization, and in vitro/in vivo release]</article-title><source>Zhongguo Yi Xue Ke Xue Yuan Xue Bao</source><year>2008</year><volume>30</volume><fpage>491</fpage><lpage>497</lpage><pub-id pub-id-type="pmid">18795627</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_122"><label>[122]</label><element-citation publication-type="journal"><name name-style="western"><surname>Holladay</surname><given-names>C</given-names></name><name name-style="western"><surname>Power</surname><given-names>K</given-names></name><name name-style="western"><surname>Sefton</surname><given-names>M</given-names></name><comment>et al</comment><article-title>Functionalized scaffold-mediated interleukin 10 gene delivery significantly improves survival rates of stem cells in vivo</article-title><source>Mol Ther</source><year>2011</year><volume>19</volume><fpage>969</fpage><lpage>978</lpage><pub-id pub-id-type="pmid">21266957</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mt.2010.311</pub-id><pub-id pub-id-type="pmcid">PMC3086863</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_123"><label>[123]</label><element-citation publication-type="journal"><name name-style="western"><surname>Amend</surname><given-names>A</given-names></name><name name-style="western"><surname>Wickli</surname><given-names>N</given-names></name><name name-style="western"><surname>Sch&#228;fer</surname><given-names>AL</given-names></name><comment>et al</comment><article-title>Dual Role of Interleukin-10 in Murine NZB/W F1 Lupus</article-title><source>Int J Mol Sci</source><year>2021</year><volume>22</volume><fpage>1347</fpage><pub-id pub-id-type="pmid">33572870</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22031347</pub-id><pub-id pub-id-type="pmcid">PMC7866297</pub-id></element-citation></ref><ref id="j_rir-2023-0020_ref_124"><label>[124]</label><element-citation publication-type="journal"><name name-style="western"><surname>Biswas</surname><given-names>S</given-names></name><name name-style="western"><surname>Bieber</surname><given-names>K</given-names></name><name name-style="western"><surname>Manz</surname><given-names>RA</given-names></name><article-title>IL-10 revisited in systemic lupus erythematosus</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>970906</fpage><pub-id pub-id-type="pmid">35979356</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.970906</pub-id><pub-id pub-id-type="pmcid">PMC9376366</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>